Quest Diagnostics potvrdila kybernetický útok na systém Quanum, při němž došlo k neoprávněnému zpřístupnění osobních údajů a zdravotnických záznamů pacientů. Firma zatím neuvedla počet dotčených pacientů.
Medical lab testing giant Quest Diagnostics has confirmed a cyberattack and data breach affecting an as-yet unspecified amount of sensitive patient information stored in its systems, according to a legally required disclosure with U.S. regulators.
Quest said in an 8-K filing with the U.S. Securities and Exchange Commission that it learned of a cyberattack on Wednesday targeting one of its lab testing systems, Quanum, which allows doctors’ offices, hospitals, and healthcare practices to request lab tests for patients while also handling billing. The platform stores a large amount of patient health and medical records, as well as associated diagnostic and billing data.
The company said the unauthorized access included the accessing of “certain patient records.” Quest said it notified law enforcement and is investigating.
The cyberattack on Quest is the latest major cyber incident to affect the healthcare industry this year. A series of cyberattacks and data breaches have sparked weeks of disruption and allowed the theft of millions of patient electronic health records and other medical information. Health tech companies have become a major target for financially motivated cybercriminals, who aim to steal as much sensitive data as possible and threaten to publish it if they aren’t paid a ransom.
In recent months, a cyberattack resulted in the mass-wiping of employee devices at medical tech maker Stryker in March, and a hack on medical implant manufacturer Boston Scientific in August forced the company’s network offline for weeks, sparking “global disruption” to its operations. Meanwhile, separate hacks throughout the year caused massive breaches of patient data at medical recordkeeping company CareCloud, Scotland-based health tech provider Craneware, and U.S. pharmaceutical distribution giant McKesson.
The lab-testing giant has not yet said how many healthcare customers, or patients, had information stolen during the attack on its Quanum systems.
Quest’s website and materials say Quanum is used by about half a million clinicians in thousands of locations across North America. It’s unclear how many health records Quanum holds, but one 2026 case study on Quest’s website shows how a single health system with more than 6 million patients can hold hundreds of millions of related medical documents and charts.
Quest did not say when the breach began or whether any hacking group has contacted the company with demands, such as payment in exchange to not release the stolen data. Amanda Rivera, a spokesperson for Quest, did not answer TechCrunch’s questions about the incident and referred to its security notice.
In the notice, Quest said that some patients’ protected health information was taken, including “personal information and patient records,” but the company is still investigating what specific kinds of data were taken. (The website post currently contains “noindex” code, which tells search engines not to list the page in search results, making it far more difficult for people to find the page.)
This is Quest’s second known major data breach in a decade, after losing 11.9 million patient records in a cyberattack on a third-party billing company in 2019.
Do you work at Quest Diagnostics or know more about the data breach? We’d love to hear from you. You can reach this reporter on Signal at the username zackwhittaker.1337 or by email [email protected].
Updated with a response from Quest.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
Zack Whittaker is the security editor at TechCrunch. He also authors the weekly cybersecurity newsletter, this week in security.
He can be reached via encrypted message at zackwhittaker.1337 on Signal. You can also contact him by email, or to verify outreach, at [email protected].
Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth
Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025
Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion
Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35
, /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.
"We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI," said Jim Davis, Chairman, CEO and President. "Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year."
Recent Highlights:
Announced the ability for iPhone and iPad users in the United States to conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app, available to the public later this year.
Finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. Continued to advance our Co-Lab Solutions implementation and joint venture lab with Corewell Health in Michigan.
Extended our AD-Detect® menu to include the FDA-cleared Roche Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test and launched a new AD-Detect test panel with pTau217, amyloid beta and APOE to help guide diagnosis and treatment decisions for Alzheimer's disease.
Advanced Project Nova from the design phase to the solutions-build phase and continue to expect to deploy Epic solutions in our first lab in the fall of 2027.
The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange. Additional information will be provided closer to the event.
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
Change
2026
2025
Change
(dollars in millions, except per share data)
Reported:
Net revenues
$ 3,097
$ 2,816
10.0 %
$ 9,035
$ 8,229
9.8 %
Diagnostic Information Services revenues
$ 3,035
$ 2,755
10.2 %
$ 8,845
$ 8,043
10.0 %
Revenue per requisition
(4.2) %
(2.8) %
Requisition volume
14.5 %
12.9 %
Organic requisition volume
14.4 %
12.8 %
Operating income (a)
$ 479
$ 386
24.2 %
$ 1,337
$ 1,170
14.3 %
Operating income as a percentage of net revenues (a)
15.5 %
13.7 %
1.8 %
14.8 %
14.2 %
0.6 %
Net income attributable to Quest Diagnostics (a)
$ 312
$ 245
27.6 %
$ 884
$ 747
18.4 %
Diluted EPS (a)
$ 2.78
$ 2.16
28.7 %
$ 7.86
$ 6.57
19.6 %
Cash provided by operations
$ 611
$ 563
8.8 %
$ 1,486
$ 1,421
4.6 %
Capital expenditures
$ 166
$ 144
15.0 %
$ 418
$ 369
13.2 %
Adjusted (a):
Operating income
$ 517
$ 458
13.0 %
$ 1,466
$ 1,330
10.3 %
Operating income as a percentage of net revenues
16.7 %
16.3 %
0.4 %
16.2 %
16.2 %
— %
Net income attributable to Quest Diagnostics
$ 338
$ 296
14.2 %
$ 969
$ 845
14.7 %
Diluted EPS
$ 3.00
$ 2.60
15.4 %
$ 8.62
$ 7.43
16.0 %
(a)
For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.
Updated Guidance for Full Year 2026
The company updates its full year 2026 guidance as follows:
Updated Guidance
Prior Guidance
Low
High
Low
High
Net revenues
$12.065 billion
$12.105 billion
$11.95 billion
$12.05 billion
Net revenues increase
9.3 %
9.7 %
8.3 %
9.2 %
Reported diluted EPS
$10.21
$10.31
$9.97
$10.17
Adjusted diluted EPS
$11.25
$11.35
$11.05
$11.25
Cash provided by operations
Approximately $1.90 billion
Approximately $1.80 billion
Capital expenditures
Approximately $550 million
Approximately $550 million
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on October 22, 2026 until midnight Eastern Time on November 5, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, the impact of the incident described in the Current Report on Form 8-K filed on October 22, 2026, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
Net revenues
$ 3,097
$ 2,816
$ 9,035
$ 8,229
Operating costs and expenses and other operating income:
Cost of services
2,055
1,867
6,024
5,474
Selling, general and administrative
523
501
1,556
1,463
Amortization of intangible assets
37
39
112
117
Other operating expense, net
3
23
6
5
Total operating costs and expenses, net
2,618
2,430
7,698
7,059
Operating income
479
386
1,337
1,170
Other income (expense):
Interest expense, net
(61)
(66)
(187)
(200)
Other (expense) income, net
(2)
8
12
18
Total non-operating expense, net
(63)
(58)
(175)
(182)
Income before income taxes and equity in earnings of equity method investees
416
328
1,162
988
Income tax expense
(99)
(77)
(261)
(233)
Equity in earnings of equity method investees, net of taxes
9
8
23
35
Net income
326
259
924
790
Less: Net income attributable to noncontrolling interests
14
14
40
43
Net income attributable to Quest Diagnostics
$ 312
$ 245
$ 884
$ 747
Earnings per share attributable to Quest Diagnostics' common stockholders:
Basic
$ 2.82
$ 2.18
$ 7.97
$ 6.66
Diluted
$ 2.78
$ 2.16
$ 7.86
$ 6.57
Weighted average common shares outstanding:
Basic
110
112
110
112
Diluted
112
113
112
113
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
September 30, 2026 and December 31, 2025
(in millions, except per share data)
(unaudited)
September 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$ 797
$ 420
Accounts receivable, net
1,712
1,408
Inventories
218
189
Prepaid expenses and other current assets
390
361
Total current assets
3,117
2,378
Property, plant and equipment, net
2,275
2,203
Operating lease right-of-use assets
670
657
Goodwill
9,112
8,945
Intangible assets, net
1,634
1,636
Investments in equity method investees
139
136
Other assets
274
270
Total assets
$ 17,221
$ 16,225
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses
$ 1,643
$ 1,600
Current portion of long-term debt
10
504
Current portion of long-term operating lease liabilities
181
174
Total current liabilities
1,834
2,278
Long-term debt
5,540
5,167
Long-term operating lease liabilities
554
537
Other liabilities
1,262
957
Redeemable noncontrolling interest
81
80
Stockholders' equity:
Quest Diagnostics stockholders' equity:
Common stock, par value $0.01 per share; 600 shares authorized as of both September 30, 2026
and December 31, 2025; 162 shares issued as of both September 30, 2026 and December 31, 2025
2
2
Additional paid-in capital
2,397
2,381
Retained earnings
10,593
9,994
Accumulated other comprehensive loss
(66)
(27)
Treasury stock, at cost; 52 shares as of both September 30, 2026 and December 31, 2025
(5,294)
(5,180)
Total Quest Diagnostics stockholders' equity
7,632
7,170
Noncontrolling interests
318
36
Total stockholders' equity
7,950
7,206
Total liabilities and stockholders' equity
$ 17,221
$ 16,225
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2026 and 2025
(in millions)
(unaudited)
Nine Months Ended
September 30,
2026
2025
Cash flows from operating activities:
Net income
$ 924
$ 790
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
440
425
Provision for credit losses
5
2
Deferred income tax expense
155
118
Stock-based compensation expense
63
63
Other, net
22
37
Changes in operating assets and liabilities:
Accounts receivable
(308)
(153)
Accounts payable and accrued expenses
244
113
Income taxes payable
(24)
(1)
Other assets and liabilities, net
(35)
27
Net cash provided by operating activities
1,486
1,421
Cash flows from investing activities:
Business acquisitions, net of cash acquired
(39)
(51)
Capital expenditures
(418)
(369)
Other investing activities, net
2
(20)
Net cash used in investing activities
(455)
(440)
Cash flows from financing activities:
Proceeds from borrowings
494
410
Repayments of debt
(504)
(1,011)
Purchases of treasury stock
(252)
(150)
Exercise of stock options
108
61
Employee payroll tax withholdings on stock issued under stock-based compensation plans
(40)
(44)
Dividends paid
(279)
(263)
Distributions to noncontrolling interest partners
(35)
(43)
Contributions from noncontrolling interest partners
25
—
Other financing activities, net
(169)
(61)
Net cash used in financing activities
(652)
(1,101)
Effect of exchange rate changes on cash and cash equivalents and restricted cash
(2)
3
Net change in cash and cash equivalents and restricted cash
377
(117)
Cash and cash equivalents and restricted cash, beginning of period
420
549
Cash and cash equivalents and restricted cash, end of period
$ 797
$ 432
Cash paid during the period for:
Interest
$ 151
$ 167
Income taxes
$ 142
$ 112
Notes to Financial Tables
1) The computation of basic and diluted earnings per common share is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
(in millions, except per share data)
Amounts attributable to Quest Diagnostics' common stockholders:
Net income attributable to Quest Diagnostics
$ 312
$ 245
$ 884
$ 747
Less: earnings allocated to participating securities
2
2
4
4
Earnings available to Quest Diagnostics' common stockholders - basic and diluted
$ 310
$ 243
$ 880
$ 743
Weighted average common shares outstanding - basic
110
112
110
112
Effect of dilutive securities:
Stock options and performance share units
2
1
2
1
Weighted average common shares outstanding - diluted
112
113
112
113
Earnings per share attributable to Quest Diagnostics' common stockholders:
Basic
$ 2.82
$ 2.18
$ 7.97
$ 6.66
Diluted
$ 2.78
$ 2.16
$ 7.86
$ 6.57
2) The following tables reconcile reported GAAP results to non-GAAP adjusted results:
Three Months Ended September 30, 2026
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 479
15.5 %
$ (99)
$ 9
$ 312
$ 2.78
Restructuring and integration charges (a)
3
0.1
—
—
3
0.02
Other charges (b)
4
0.1
—
—
4
0.03
Gains and losses on investments (c)
—
—
(1)
1
3
0.02
Other gains (d)
(6)
(0.2)
1
—
(5)
(0.04)
Amortization expense
37
1.2
(10)
—
27
0.24
ETB
—
—
(6)
—
(6)
(0.05)
As adjusted
$ 517
16.7 %
$ (115)
$ 10
$ 338
$ 3.00
Nine Months Ended September 30, 2026
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 1,337
14.8 %
$ (261)
$ 23
$ 884
$ 7.86
Restructuring and integration charges (a)
14
0.2
(3)
—
11
0.10
Other charges (b)
9
0.1
—
—
9
0.08
Gains and losses on investments (c)
—
—
(3)
7
7
0.06
Other gains (d)
(6)
(0.1)
1
—
(5)
(0.04)
Amortization expense
112
1.2
(29)
—
83
0.74
ETB
—
—
(20)
—
(20)
(0.18)
As adjusted
$ 1,466
16.2 %
$ (315)
$ 30
$ 969
$ 8.62
Three Months Ended September 30, 2025
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 386
13.7 %
$ (77)
$ 8
$ 245
$ 2.16
Restructuring and integration charges (a)
11
0.4
(2)
—
9
0.07
Other charges (b)
22
0.8
(6)
—
16
0.15
Amortization expense
39
1.4
(10)
—
29
0.25
ETB
—
—
(3)
—
(3)
(0.03)
As adjusted
$ 458
16.3 %
$ (98)
$ 8
$ 296
$ 2.60
Nine Months Ended September 30, 2025
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 1,170
14.2 %
$ (233)
$ 35
$ 747
$ 6.57
Restructuring and integration charges (a)
37
0.5
(9)
—
28
0.24
Other charges (b)
52
0.6
(12)
—
40
0.36
Gains and losses on investments (c)
—
—
1
(1)
(2)
(0.01)
Other gains (d)
(46)
(0.5)
14
(8)
(40)
(0.36)
Amortization expense
117
1.4
(30)
—
87
0.76
ETB
—
—
(15)
—
(15)
(0.13)
As adjusted
$ 1,330
16.2 %
$ (284)
$ 26
$ 845
$ 7.43
(a)
For each of the three and nine months ended September 30, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
(dollars in millions)
Cost of services
$ 1
$ 1
$ 3
$ 8
Selling, general and administrative
2
10
11
29
Operating income
$ 3
$ 11
$ 14
$ 37
(b)
The three and nine months ended September 30, 2026 and 2025 include pre-tax losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense, net. Additionally, both the three and nine months ended September 30, 2025 include a $15 million pre-tax charge to earnings related to legal matters, recorded in other operating expense, net. Also, the three and nine months ended September 30, 2025 include pre-tax impairment charges of $5 million and $29 million, respectively, on certain long-lived assets related to the exit of a business, also recorded in other operating expense, net.
(c)
For all periods presented, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes, and other (expense) income, net.
(d)
Both the three and nine months ended September 30, 2026 primarily include $4 million of pre-tax gains, recorded in selling, general and administrative expenses, related to insurance recoveries for certain legal matters. The nine months ended September 30, 2025 includes a $46 million pre-tax gain, recorded in other operating expense, net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act associated with the retention of employees. Additionally, the nine months ended September 30, 2025 includes an $8 million pre-tax gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease.
(e)
For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025. No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.
3)
The outlook for adjusted diluted EPS represents management's estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:
Low
High
Diluted EPS
$ 10.21
$ 10.31
Restructuring and integration charges (a)
0.13
0.13
Amortization expense (b)
0.99
0.99
Other charges (c)
0.11
0.11
Gains and losses on investments (d)
0.06
0.06
Other gains (e)
(0.04)
(0.04)
ETB
(0.21)
(0.21)
Adjusted diluted EPS
$ 11.25
$ 11.35
(a)
Represents estimated pre-tax charges of $20 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.
(b)
Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.
(c)
Principally represents estimated pre-tax net losses of $9 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.
(d)
Represents gains and losses associated with changes in the carrying value of our strategic investments. Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.
(e)
Principally represents a pre-tax gain related to insurance recoveries for certain legal matters. Income tax impacts were primarily calculated using a combined statutory income tax rate of 25.5%.
Společnosti Waters a Quest Diagnostics od začátku roku 2027 zpřístupní domácí samoodběrový test BD Onclarity HPV, který FDA schválil pro domácí použití v dubnu 2026.
Patients across the U.S. will soon have access to a new cervical cancer test collected from the comfort of their own home—no stirrups, speculum, or in-person doctor’s visit needed.
The life sciences company Waters is partnering with Quest Diagnostics to make Waters’ BD Onclarity HPV assay test available for use at home. The partnership, announced Tuesday, will begin making self-collection kits available in early 2027. The kit was cleared by the Food and Drug Administration for at-home use in April 2026.
The test, which needs to be ordered by a clinician, will be delivered to patients. They can then collect a dry swab specimen and ship it back for testing, or drop it off at one of 2,000 Quest service centers.
The companies say the availability will allow cervical cancer screening to reach otherwise unserved or underserved populations.
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
A need for preventionInfection with HPV—a virus typically transmitted through sexual activity—can be linked to nearly every case of cervical cancer. While most HPV types resolve on their own, certain high-risk genotypes can lead to cervical cancer when the infection persists.
Though it is the the fourth most common cancer in women—the American Cancer Society estimates there will be 13,490 new cases and 4,200 deaths in 2026—cervical cancer is among the most successfully treated forms of cancer, according to the World Health Organization. That makes regular testing crucial for prevention, but there are barriers to access.
Factors like geography, costs, lack of insurance, or lack of time to see a doctor can keep some patients from diagnostics and treatment. For others, it’s fear of a traditional pelvic exam that drives them away from testing. And for many others, it’s lack of awareness altogether.
Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds
, /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney disease if left untreated.
Published in the journal Hypertension, a publication of the American Heart Association, the findings suggest that changing the diagnostic threshold for PA would double the detection rate, identifying thousands of high-risk patients who may otherwise be undiagnosed and untreated.
Researchers from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School conducted the study, based on deidentified results of lab tests performed by Quest on over 60,449 patients in the United States.
Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood. High blood pressure is a defining feature of the condition, though affected individuals may have other common symptoms like headaches or muscle cramps. If left untreated, several complications can occur.
In 2025, the Endocrine Society published guidelines that recommend screening for PA for all patients with high blood pressure and included criteria for diagnosing PA. However, the new study suggests these guidelines are "overly restrictive," with laboratory cutoffs for aldosterone levels that detect only the most advanced cases of the disease. The guideline update also recommends plasma renin activity (PRA), a blood test that measures the conversion of renin in the kidneys, as the initial screening test.
When the researchers applied the 2025 criteria (PRA ≤1 ng/mL/h, aldosterone levels ≥7.5 ng/dL, ARR > 15) to the patient cohort, only 13.0% of individuals were identified as positive for PA. However, a broader, "permissive" set of criteria (PRA ≤1 ng/mL/h, aldosterone levels >5 ng/dL, without an ARR requirement) applied to the same cohort identified approximately twice as many patients, 26.2%, with PA. Additionally, clinical conditions consistent with PA such as hypertension, hypokalemia, and atrial fibrillation (based on insurance claim billing), were enriched among patients categorized as positive for PA by the more permissive laboratory cutoffs.
Among patients identified by the more permissive criteria, a PRA score of < 0.5 ng/mL/hr had 1.27 times higher odds of having hypertension compared to those with a higher (or normal) PRA (P < 0.0001). Patients with a PRA of < 0.25 ng/mL/hr had 2.62 times higher odds of having atrial fibrillation (P = 0.0032). 79.0% of the additional patients identified by permissive criteria were missed by the 2025 criteria because they had aldosterone levels between 5 and 7.5 ng/dL, below the ES cutoff, while approximately one in five had aldosterone levels that met the ES criteria but did not meet the ARR threshold.
The findings suggest the 2025 guidelines may guide physicians to identify only the more advanced forms of the disease and that primary aldosteronism should be viewed as a spectrum rather than a positive or negative diagnosis of disease. Earlier detection using more relaxed diagnostic criteria may help clinicians identify and intervene with care with potential to prevent long-term cardiovascular complications.
"Our findings demonstrate that current international clinical guidelines for diagnosing primary aldosteronism are optimized to identify advanced disease but may be less sensitive for earlier or milder forms of PA," said lead author Marco Marcelli, MD, a board-certified endocrinologist and Medical Director at Quest Diagnostics. "Some patients with PA spend years on a diagnostic journey before learning their hypertension, headaches and other symptoms are due to a highly treatable condition. More expansive screening and diagnostic criteria may help the medical community to quickly identify these individuals hiding in plain sight before irreversible heart damage and other adverse outcomes have occurred."
The study's strengths include its large patient cohort and its limitations include its retrospective design and lack of confirmatory testing.
Primary aldosteronism is a serious condition that affects as many as 5-10% of adults with high blood pressure. Up to 25-30% of patients with hypertension may be diagnosed with PA if the criteria identified by the Quest group will eventually be confirmed in prospective studies. High blood pressure is widely prevalent in the U.S., affecting nearly half of all adults (almost 120 million individuals). For many years, PA was considered uncommon; however, a 2024 study published in Hypertension by researchers at Quest Diagnostics shows PA is likely under-detected.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
Společnost Quest Diagnostics má ve 3. čtvrtletí vykázat tržby ve výši 3,04 miliardy USD, což představuje meziroční nárůst o 8,1 %, a zisk na akcii (EPS) 2,85 USD, meziročně vyšší o 9,6 %.
Key Takeaways Quest Diagnostics' Q3 revenues are projected to rise 8.1% to $3.04 billion, with EPS up 9.6% to $2.85.
DGX's growth may benefit from broad clinical demand, greater health plan access and collaboration volumes.
Advanced Diagnostics, AI-driven automation and Invigorate cost savings may support DGX's Q3 performance.
Quest Diagnostics (DGX - Free Report) is set to release third-quarter 2026 results on Oct. 22, before the market opens.
In the last reported quarter, the renowned diagnostics provider posted adjusted earnings per share (EPS) of $3.12, which surpassed the Zacks Consensus Estimate by 11.03%. The company beat on earnings in each of the trailing four quarters, the average surprise being 5.77%.
Q3 Estimates for DGXThe Zacks Consensus Estimate for revenues is pegged at $3.04 billion, indicating an increase of 8.1% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS suggests a 9.6% rise to $2.85.
Estimate Revision Trend Ahead of DGX’s Q3 EarningsEstimates for Quest Diagnostics’ third-quarter earnings have remained unchanged in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence DGX’s Q3 ResultsAs in the previous quarter, third-quarter 2026 revenues are expected to have been supported by broad clinical demand from physicians, hospitals and consumers and increased volume from collaborations with Corewell Health and Fresenius Medical Care.
In the physician channel, a key driver has likely been geographic expansion from greater health plan access and acquisitions. Enterprise accounts may have generated additional revenues through new customer acquisitions and expanded business with existing clients.
Quest Diagnostics Incorporated Price and EPS SurpriseGrowth in the hospital channel may have been driven by Co-Lab solutions, which leverage the company’s lab and process management expertise to optimize quality and drive cost efficiencies. In the consumer channel, as in recent quarters, the company is likely to have generated strong revenue growth from both questhealth.com and its portfolio of leading consumer health collaborations.
In the third quarter of 2026, the company is likely to have maintained momentum in Advanced Diagnostics, which includes non-routine and specialized tests across advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health areas. Offerings such as the Quest AD-Detect blood test portfolio for Alzheimer's disease, Haystack MRD, ApoB and Lp(a) as well as liverfibrosis testing for new treatments for late-stage liver disease are expected to have supported growth.
The company is also investing in AI and automation to improve laboratory efficiency and customer experiences. Front-end specimen processing automation is improving productivity, while the newly launched IntelliDraw tool aims to improve specimen collection quality and service for physician customers. Additionally, operational efficiencies and cost synergies from the Invigorate initiative are likely to have supported Quest Diagnostics' operating performance.
What Our Model Unveils for DGXPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
You can see the complete list of today’s Zacks Rank #1 Rank stocks here.
Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
HeartSciences (HSCS - Free Report) has an Earnings ESP of +2.70% and a Zacks Rank #2 at present. The company is expected to release second-quarter fiscal 2027 results soon.
HSCS’ earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average negative surprise being 0.06%. The Zacks Consensus Estimate for fiscal second-quarter loss per share calls for an improvement of 12.9% from the year-ago quarter’s loss.
Eastern Bank boosted its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 9.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 207,720 shares of the medical research company’s stock after acquiring an additional 17,751 shares during the quarter. Eastern Bank owned 0.19% of Quest Diagnostics worth $48,413,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Quest Diagnostics during the second quarter worth about $1,965,923,000. EdgePoint Investment Group Inc. boosted its holdings in Quest Diagnostics by 35.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock worth $439,753,000 after buying an additional 582,797 shares during the last quarter. Bank of America Corp DE purchased a new stake in Quest Diagnostics during the 2nd quarter worth approximately $410,151,000. Dimensional Fund Advisors LP increased its stake in Quest Diagnostics by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock worth $382,085,000 after buying an additional 17,987 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Quest Diagnostics by 11.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock valued at $199,743,000 after acquiring an additional 95,804 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.
Analysts Set New Price Targets A number of analysts have recently issued reports on the company. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. Barclays raised their price objective on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. JPMorgan Chase & Co. lifted their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a report on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $237.08.
Read Our Latest Research Report on DGX Quest Diagnostics Trading Down 0.6% Shares of DGX traded down $1.47 during midday trading on Monday, reaching $231.87. The company had a trading volume of 308,272 shares, compared to its average volume of 971,476. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $248.84. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The firm has a 50 day simple moving average of $237.97 and a 200-day simple moving average of $212.96. The stock has a market cap of $25.59 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 2.13 and a beta of 0.54.
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the previous year, the company posted $2.62 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Research analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.
Quest Diagnostics Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics’s dividend payout ratio is 36.52%.
Insider Transactions at Quest Diagnostics In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 22,677 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the completion of the sale, the senior vice president owned 37,557 shares of the company’s stock, valued at $9,130,482.27. This trade represents a 37.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the sale, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 34,277 shares of company stock worth $8,316,493 in the last 90 days. Insiders own 0.88% of the company’s stock.
(Free Report)
Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals, health plans, employers and other organizations diagnose, monitor and manage medical conditions.
Its services include routine blood and other clinical laboratory tests, advanced and molecular diagnostics, anatomic pathology, genetic and genomic testing, and testing related to infectious diseases. Quest also provides employer health screening, drug testing, clinical trial support and laboratory information services.
Read More Five stocks we like better than Quest Diagnostics What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks Insiders Are Selling These 3 Stocks, Should You? Datadog’s Rally Has Insiders Selling—Can It Keep Climbing?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Studie v The Journal of Molecular Diagnostics ukázala, že Haystack MRD dosáhl u kolorektálního karcinomu 100% specificity bez falešně pozitivních výsledků při 3letém i 5letém sledování a senzitivity 100 % a 83,3 %.
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence
, /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series. The study also validated the test’s analytical performance across 23 solid tumor types. Provided by Quest Diagnostics (NYSE: DGX), Haystack MRD is an ultrasensitive circulating tumor DNA (ctDNA) liquid biopsy test for identifying residual or recurrent disease in patients with solid tumor cancers.
The study evaluated the clinical performance of the commercially available Haystack MRD test by retrospectively testing residual specimens from patients enrolled in the DYNAMIC and DYNAMIC-III trials, which evaluated the use of ctDNA-based MRD results (generated with an earlier version of the Haystack MRD technology) to guide chemotherapy decisions in stage II and III colorectal cancer. In this cohort, Haystack MRD results were highly associated with recurrence, demonstrating 100% sensitivity and 100% specificity at 3-year follow-up and 83.3% sensitivity and 100% specificity at 5-year follow-up. Haystack MRD also substantially outperformed carcinoembryonic antigen (CEA), a standard blood-based biomarker, detecting recurrence with 88.9% sensitivity versus 11.1% for CEA (median follow-up 60 months).
Scientists from Quest and Haystack Oncology conducted the study together with investigators from the two institutions that led the DYNAMIC trials: The Walter and Eliza Hall Institute of Medical Research and the Peter MacCallum Cancer Center in Melbourne, Australia.
"The DYNAMIC trial demonstrated the potential for ctDNA to guide more individualized treatment decisions in stage II colon cancer but realizing that potential depends on a highly sensitive assay that can reliably detect the extremely small amounts of tumor DNA that may remain after treatment, while maintaining high specificity," said Professor Jeanne Tie,* a medical oncologist at Peter MacCallum Cancer Centre and lead investigator for the DYNAMIC trial series. "This study helps bridge the gap between clinical research and real-world patient care."
In other key findings, Haystack MRD:
Demonstrated ultrasensitive detection of residual disease, with a 95% limit of detection (LoD95) of 0.063 mean ctDNA molecules per milliliter (mL) of plasma. Earlier validation established an LoD95 of 6 parts per million (PPM), a metric commonly reported for tumor-informed MRD assays1. Achieved sub-PPM detection of 0.8 PPM, and as low as 0.2 PPM in some samples, with no false positives in cancer-free controls using an investigational whole-genome version of the test. This whole-genome version is currently only available to clinical investigators and biopharma partners while the commercial test uses whole-exome sequencing. Established a limit of quantitation (LOQ) suitable for response monitoring of 0.25 mean ctDNA molecules per mL. Establishing the LOQ allows a change in a patient's ctDNA level between serial tests to be interpreted as a real change in tumor burden rather than assay variability. Demonstrated analytical performance across the complete testing process, starting from plasma collection and including cell free (cf) DNA extraction, rather than starting with already extracted cfDNA. As a result, analytical performance can be directly translated to clinical performance, versus assay validations that begin with extracted cfDNA and do not account for extraction variability. "To our knowledge, this is the first time that the full ctDNA MRD testing process, starting from plasma collection and including cfDNA extraction, has been characterized for the limit of detection (at 95%) and quantitative analytical performance," said study co-author Dan Edelstein, Vice President and General Manager, Haystack Oncology. "The precise quantitative measurements demonstrated in this validation provide confidence that the Haystack MRD test accurately measures changes in ctDNA levels over time and can be used for serial ctDNA monitoring during and after treatment. With these insights, clinicians can understand the degree of change in ctDNA levels related to tumor biology in an individual patient, supporting earlier evaluation of treatment response and detection of molecular progression or recurrence."
In addition, the study examined a real-world clinical cohort from an Early Experience program in which Haystack MRD detected ctDNA across 27 solid tumor types, including at ultra-low concentrations, with 42% of positive results below 0.5 mean ctDNA molecules/mL.
The new study adds to the growing body of evidence supporting the clinical value of Haystack MRD, following two studies published in The New England Journal of Medicine. Published in 2022, DYNAMIC was the first prospective, interventional study to demonstrate the clinical utility of ctDNA-based MRD testing to reduce the use of chemotherapy in stage II colon cancer without compromising recurrence-free survival. In 2025, a study on response to immunotherapy in mismatch repair-deficient cancers found that the Haystack MRD test was a "reliable liquid biopsy surrogate" that identified clinical complete response at a median of 1.4 months, compared with more than 6 months using imaging.
*Dr. Tie has served as an advisor and consultant for Haystack Oncology.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD, a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual or recurrent disease with exceptional sensitivity and specificity. Haystack Oncology works with biopharmaceutical companies to accelerate and inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test (LDT) by Quest Diagnostics. The FDA granted Haystack MRD Dx Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device by Haystack Oncology in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. Haystack MRD is now authorized for patient access in all 50 U.S. states. www.haystackmrd.com
Prathapam R, Champion K, Blakely K, et al. Analytical validation of the Haystack MRD assay for the detection of extremely low ctDNA in solid tumor patients. Poster presented at: Association for Molecular Pathology 2024 Annual Meeting and Expo; November 19, 2024; Vancouver, BC, Canada. doi:10.1016/S1525-1578(24)00232-0 SOURCE Quest Diagnostics
Quest Diagnostics letos zatím posílil o 36,3 % díky silné poptávce po pokročilé diagnostice, novým zákazníkům a růstu v kanálech lékařů, nemocnic i spotřebitelů.
Key Takeaways Quest Diagnostics' shares have rallied 36.3% YTD on strong momentum across its business.DGX is benefiting from advanced diagnostics, new customers, acquisitions and channel growth.DGX is using AI, automation and Invigorate to improve efficiency and target annual cost savings. Quest Diagnostics’ (DGX - Free Report) shares have rallied 36.3% so far this year, highlighting strong momentum. The stock has outperformed the industry, which has gained 20%, as well as the S&P 500 composite, which has risen 12%.
Carrying a Zacks Rank #2 (Buy) at present, the renowned clinical laboratory benefits from growing momentum in advanced diagnostics, with strong demand across key testing areas and continued expansion in oncology. The company is seeing broad-based growth across its physician, hospital and consumer-testing channels. The greater adoption of AI and automation is driving efficiency, productivity gains and cost savings across laboratory operations.
Headquartered in Secaucus, NJ, Quest Diagnostics provides diagnostic information services to a broad range of customers within its primary channels of physicians, hospitals, patients and consumers. The company is a key provider of reference testing for approximately half of U.S. hospitals. Quest Diagnostics has pursued growth through strategic acquisitions and seeks to drive operational excellence across the customer value chain and its business.
Factors Favoring DGX’s GrowthThe rally in the share price can be linked to the company’s ongoing momentum in advanced diagnostics, mainly in advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health areas. Several of these areas delivered double-digit revenue growth in the second quarter of 2026. Demand remained elevated for ApoB, Lp(a) and liver fibrosis tests, while the company continued to grow its analyzer solution for autoimmune disorders. Quest Diagnostics advanced Haystack molecular resiMRD during the quarter, securing New York State approval that allows commercialization across all 50 states. The company also expanded access to cancer tests through Flatiron Health’s OncoEMR Molecular Profiling Integration platform.
Quest Diagnostics’ physician channel revenues are benefiting from new customer wins, higher business with existing customers and growth in regions where it expanded health plan access and completed acquisitions. The Fresenius Medical Care collaboration is also broadening its capabilities in kidney care. Hospital channel revenues also grew at a double-digit rate, primarily from Co-Lab Solutions with Corewell Health.
Image Source: Zacks Investment Research
The consumer-testing channel, QuestHealth.com, continued to drive revenue growth, supported by demand for wellness panels and newer services like thyroid testing. The platform is also attracting consumer, wearable and wellness partners through flexible technology integration.
On a broader note, rising chronic disease rates and growing demand for early diagnosis are also expected to support the clinical laboratory testing market and Quest Diagnostics’ long-term growth prospects.
Operationally, the company uses automation and AI across laboratory and administrative processes to offset labor, benefit and reimbursement pressures while improving service quality. During the second quarter, Quest Diagnostics expanded AI-enabled cervical cancer screening and front-end specimen-processing automation to additional laboratories. It also launched IntelliDraw to guide specimen collection at physician offices and plans to introduce an AI-based supply tool at patient service centers. The Invigorate program continues to target 3% annual cost savings and productivity improvements.
Concerns for DGXQuest Diagnostics’ high leverage remains a concern, with $5.63 billion in long-term debt and $626 million in cash as of June 30, 2026. The company also remains exposed to changes in government reimbursement, health policy and payer bargaining power. Cost inflation could weigh on its margin growth.
A Glance at DGX’s EstimatesThe Zacks Consensus Estimate for Quest Diagnostics’ 2026 and 2027 earnings per share (EPS) is expected to increase 13.2% and 7.3%, respectively, to $11.15 and $11.97. In the past 60 days, the Zacks Consensus Estimate for the company's 2026 EPS has risen 1.6%.
Revenues for 2026 are projected to grow 8.9% to $12.01 billion, followed by a 4.6% jump to $12.56 billion in 2027.
Other Key PicksSome other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 45.2% compared with the industry’s 3.3% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 12.7% against the industry’s 27.9% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 33.3% compared with the industry’s 3.3% growth over the past year.
Quest Diagnostics uvedla, že její růst překonává dřívější plán díky organickému růstu, poptávce po spotřebitelském testování a partnerstvím. V roce 2026 očekává růst tržeb téměř 8 % a zisku více než 13 %, téměř 14 %.
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
Davis said Quest had previously targeted 4% to 5% revenue growth, including 1% to 2% from acquisitions, along with 7% to 9% earnings-per-share growth. He said revenue rose about 12% in 2025 and earnings grew just above 10%. For 2026, Quest has guided for revenue growth of nearly 8% and earnings growth of more than 13%, approaching 14%.
While Quest had initially contemplated $1.5 billion in mergers and acquisitions, Davis said the company has deployed $2.8 billion of capital in M&A since 2024. Its acquisition activity was concentrated in 2024, including LifeLabs in Canada and outreach laboratory transactions involving Allina Health, OhioHealth and University Hospitals, among others. Since then, Quest has focused on integrating those operations while also taking on large partnership-related businesses that were not structured as acquisitions. Those include a co-lab arrangement with Corewell Health that Davis described as a $250 million business, as well as laboratory testing previously handled by Fresenius for dialysis patients, representing about $100 million in business.
Organic Growth Drivers Davis said Quest’s core physician-office business remains structurally stronger than it was before the COVID-19 pandemic. He cited the aging population, continued prevalence of chronic conditions and the expanding use of newer tests.
Quest expects to test 250 million people in 2026, representing an estimated 110 million to 120 million unique individuals, Davis said. The company continues to see elevated levels of diabetes, cardiovascular disease, liver disease and other chronic conditions across the population it serves.
He also highlighted growing adoption of tests associated with cardiovascular risk and metabolic health, including Lp(a), ApoB and insulin-resistance testing. Blood-based biomarkers used in assessing Alzheimer’s disease are gaining traction beyond neurologists and are increasingly being used in primary care, Davis said.
“People are proactively getting lab work,” Davis said, describing a broader consumer trend toward monitoring biomarkers and biometric data before deciding whether to visit a physician.
Quest’s consumer-health business, which includes its QuestHealth.com direct-to-consumer operations and partnerships with Function Health, Junction Health, Hims & Hers, Hone Health, WHOOP, Oura and Apple Health, was a $250 million business at the end of 2025 and was expected to grow at least 30% in 2026, according to Davis. Apple Health was not expected to begin contributing until December.
Davis said direct-to-consumer wellness testing has higher average margins than the company overall because it is cash-pay business, avoiding insurance denials and patient concessions. He said Quest can also leverage its existing patient service center and courier infrastructure as volumes increase.
Health-System Partnerships and Market Expansion Quest has used health-system outreach arrangements to build its presence in markets where independent physician practices are less prevalent. Davis pointed to Minneapolis, Cleveland and Columbus, Ohio, where large health systems employ a substantial share of primary-care physicians and laboratory work has historically remained within those systems.
Following outreach transactions with health systems in those markets, Quest has begun generating growth above the business volumes it initially purchased, Davis said. The company has expanded its commercial presence, logistics network and patient service centers after entering those regions.
Corewell Health is expected to be an important part of Quest’s Michigan strategy. Quest currently operates laboratories inside Corewell’s 21 hospitals, but Davis said outreach work from those facilities will move next year into a jointly operated central laboratory in Southfield, Michigan.
Quest will also contribute its legacy Michigan business to that laboratory, which Davis said will become the state’s largest lab and will compete for additional testing business. The economics of the Corewell arrangement are expected to improve over a three-year period as Quest transitions equipment and supplies to its preferred vendors and realizes scale benefits.
For the Fresenius testing business, Davis said Quest expects margins to reach the company average by the fourth quarter of 2026 and become accretive to the company average in 2027.
PAMA Remains an Uncertainty Davis also addressed the potential impact of the federal Protecting Access to Medicare Act, or PAMA, which could affect Medicare laboratory reimbursement rates. He said the company is awaiting details from the Centers for Medicare & Medicaid Services on participation in the recent data-collection process.
Quest plans to challenge the results if participation falls materially short of broad industry representation, Davis said. He noted that fewer than 1% of eligible laboratories submitted data during the prior collection process in 2016, which he said produced an unrepresentative pricing profile.
The company is also supporting the RESULTS Act, a bipartisan proposal Davis said would simplify data collection and provide a more accurate measure of market-based pricing. The legislation had 130 co-sponsors, according to Davis, though he said he could not assign a probability to either passage of the bill or a further PAMA delay.
In a worst-case scenario in which every affected test rate fell by the maximum 15%, Davis estimated Quest’s exposure at somewhat more than $100 million. He added that Medicare fee-for-service now represents less than half of the relevant business as more beneficiaries shift into Medicare Advantage plans.
About Quest Diagnostics (NYSE:DGX) Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing used to help diagnose, monitor and manage diseases and other health conditions, serving physicians, hospitals, health plans, employers, government agencies and individual consumers.
Its services include routine blood and urine testing, advanced and esoteric diagnostics, molecular and genetic testing, anatomic pathology, cancer testing, drug screening and wellness-related assessments.
Quest Diagnostics uvedla, že 29,5 % pacientů s protilátkami proti lymské borelióze mělo také protilátky proti dalšímu klíšťovému patogenu. Nejčastěji šlo o Babesia a Anaplasma.
Key Takeaways Quest Diagnostics found 29.5% of Lyme-seropositive patients had antibodies to another tick-borne pathogen.Babesia and Anaplasma were the most frequent co-seropositive pathogens identified in the study.The Northeast had the highest co-seropositivity rate, at 31.1% among Lyme-seropositive patients. Quest Diagnostics Inc. (DGX - Free Report) recently announced findings from a study published in JAMA Network Open, showing that nearly one-third of patients with antibodies against Borrelia burgdorferi, the bacterium responsible for Lyme disease, also had antibodies against at least one other tick-borne pathogen. The study analyzed de-identified test results from 193,260 individuals across the United States who underwent tick-borne disease testing between January 2021 and December 2025.
Per management, the findings highlight the frequency of tick-borne co-exposure, particularly in Lyme disease-endemic regions. The company noted that comprehensive testing can help identify multiple potential pathogens because Lyme disease, anaplasmosis and babesiosis can have overlapping symptoms, while babesiosis requires different treatment from Lyme disease.
DGX Stock Trend Following the NewsFollowing the announcement, DGX stock lost 0.6% at yesterday’s close. Year to date, shares of the company have risen 41.1% compared with the industry’s 22% growth and the S&P 500’s 13.2% gain.
The study strengthens Quest Diagnostics’ role in supporting the diagnosis of tick-borne diseases and highlights the potential need for broader testing among patients suspected of having Lyme disease. Greater awareness of co-exposure patterns could support demand for comprehensive diagnostic testing, particularly as tick-borne illnesses continue to affect patients across multiple regions of the United States.
DGX currently has a market capitalization of $27.2 billion.
Image Source: Zacks Investment Research
More on the StudyThe study found that 29.5% of individuals with antibodies against B. burgdorferi also had antibodies against at least one additional tick-borne pathogen, compared with 5.5% of individuals without Lyme disease antibodies. The most frequent co-seropositivity involved Babesia microti and Anaplasma phagocytophilum, which can be transmitted by the same blacklegged tick that carries B. burgdorferi.
Among the overall study population, 5% of individuals were seropositive for B. burgdorferi, while 3.4% were seropositive for Babesia microti, 3.1% for Anaplasma phagocytophilum and 1.0% for Ehrlichia species. The Northeast recorded the highest rate of co-seropositivity, with 31.1% of Lyme-seropositive patients showing antibodies against non-Lyme pathogens. Babesia antibodies were also most frequently co-detected in the Northeast, reaching 18.5%.
The study further found that more than 40% of diagnostic panel testing occurred during June through August, while nearly 26% took place during September through November, reflecting the seasonal nature of tick activity. The cohort was primarily represented by patients in the Northeast, which accounted for 70.6% of those tested.
Quest Diagnostics offers several laboratory tests for tick-borne infections, including a tick-borne disease antibodies panel incorporating guideline-recommended two-step serologic testing for Lyme disease. The company said the study’s large, geographically diverse dataset provides additional insight into patterns of tick-borne co-exposure, although serological findings do not establish whether an infection is currently active.
Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global Lyme disease testing market is estimated to be $13.2 billion in 2026 and is projected to witness a CAGR of 8.2% through 2030.
Factors such as the rising incidence of Lyme disease, increasing awareness among patients and healthcare professionals, growing demand for accurate diagnostic tools and advancements in serological and nucleic acid testing are supporting market growth.
Other NewsQuest Diagnostics recently announced that Apple Health app users in the United States will be able to purchase a Quest laboratory panel with more than 50 biomarkers directly through the app later this year. Priced at $119, the panel will assess cardiometabolic health and organ function and include biometric readings. Users can schedule testing at approximately 2,000 Quest patient service centers, with results delivered through the Apple Health app.
In August, Quest Diagnostics announced its plans to offer an AD-Detect-branded laboratory test service using Roche’s FDA-cleared Elecsys pTau217 blood test in the fourth quarter of 2026 to assess Alzheimer’s disease pathology. The company also plans to incorporate the Roche assay into future AD-Detect blood test panels in 2027. DGX is launching a multi-biomarker AD-Detect test designed to help identify patients with Alzheimer’s pathology.
DGX’s Zacks Rank & Key PicksQuest Diagnostics currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Inspire Medical Systems (INSP - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Inspire Medical reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
Quest Diagnostics klesly o 5,1 % poté, co CMS oznámila snížení úhrad za laboratorní práce až o 15 % od 1. ledna 2027. Firma uvedla, že z úhrad od CMS pocházelo v roce 2025 asi 11 % jejích tržeb.
Medical testing giant Quest Diagnostics (DGX -5.19%) stock slipped 5.1% through 11:30 a.m. Tuesday, after the Centers for Medicare & Medicaid Services (CMS) disclosed Monday that they've been paying about 16% more for lab work than private insurers pay.
No longer.
Effective Jan. 1, 2027, CMS says it will cut reimbursement rates for lab costs by up to 15%.
Image source: Getty Images.
What this means for Quest Diagnostics (and for you) CMS estimates the reduced reimbursement rates will save taxpayers $1 billion per year. Unfortunately for Quest Diagnostics, these savings will come directly out of its own revenue stream.
In its 10-K filing with the SEC, Quest highlighted a reduction in the rates it receives from Medicare and Medicaid as one key risk to investing in its stock, warning of "the impact upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with policies and requirements imposed by Medicare, Medicaid."
The question is: how badly might Quest be hurt?
And the answer: According to this same 10-K filing, Quest got approximately 11% of its revenue from CMS reimbursement in 2025.
Premium Feature
Moneyball Superscore
76/100
Today's Change
(
-5.19
%) $
-12.71
Current Price
$
232.18
What's next for Quest Diagnostics? And now we can do a little math. Shrinking an 11% revenue stream by 15% implies that if CMS reduces its rates by the full 15%, Quest Diagnostics' annual revenue would decrease by 1.65%. Now, Quest notes that successive 15% per year reductions are possible from 2027 through 2029. This still implies that the worst-case scenario for Quest is a reduction of slightly less than 5% in its business.
With Quest stock down 5.1%, that worst-case scenario is already more than priced into the stock today. From where I sit, that means there's little reason to expect Quest stock to keep going down after today.
It might even bounce back.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Quest Diagnostics. The Motley Fool has a disclosure policy.
Quest Diagnostics roste napříč lékařským, nemocničním i spotřebitelským kanálem, přičemž několik oblastí pokročilé diagnostiky ve 2. čtvrtletí vykázalo dvouciferný růst. Zároveň ale čelí tlaku na úhrady, nákladům a vysokému dluhu.
Key Takeaways Quest Diagnostics is seeing growth across physician, hospital and consumer channels, led by customer wins.DGX's advanced diagnostics portfolio delivered double-digit growth in several areas in the second quarter.Quest Diagnostics targets 3% annual savings, but reimbursement pressure, costs and debt remain concerns. Quest Diagnostics (DGX - Free Report) is gaining momentum across physician, hospital and consumer channels, supported by customer wins, acquisitions and expanded offerings. The company’s expanding advanced diagnostics portfolio is driving double-digit growth across key areas, with further commercialization opportunities ahead. Execution of AI, automation and digital transformation initiatives is supporting Quest Diagnostics’ cost savings and productivity goals. However, the company faces reimbursement uncertainty, cost pressures and elevated debt, which could weigh on margins and financial flexibility.
Over the past year, this Zacks Rank #2 (Buy) stock has rallied 32.6% compared with the industry’s 17.5% growth and the S&P 500 composite’s 15.1% rise.
The renowned provider of diagnostic information services has a market capitalization of $27.20 billion. The company surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 5.8%.
Factors Favoring DGXGrowth Momentum in the Base Business: Quest Diagnostics continues to address the needs of physicians, hospitals and consumers through broader access, clinical innovation and integrated service offerings. In the second quarter of 2026, physician channel revenues increased in the high single-digit range, supported by new customer wins, higher business with existing customers and growth in regions where the company expanded health plan access and completed acquisitions. The Fresenius Medical Care collaboration is also broadening Quest Diagnostics’ capabilities in kidney care.
Hospital channel revenues grew at a double-digit rate, primarily from Co-Lab Solutions with Corewell Health. Corewell is expected to add about $250 million to 2026 revenues, and the joint venture laboratory is scheduled to be launched in early 2027. The consumer-testing platform, QuestHealth.com, continued to generate revenue growth, supported by demand for wellness panels and newer services such as thyroid testing. The platform is also attracting consumer, wearable and wellness partners through flexible technology integration.
Image Source: Zacks Investment Research
Strong Potential of Advanced Diagnostics: Quest Diagnostics is expanding advanced diagnostics across cardiometabolic and endocrine, autoimmune, brain health, oncology and women’s and reproductive health. Several of these areas delivered double-digit revenue growth in the second quarter of 2026. Demand remained elevated for ApoB, Lp(a) and liver fibrosis tests, while the company continued to grow its analyzer solution for autoimmune disorders.
In brain health, the AD-Detect portfolio again produced double-digit growth. In oncology, New York State approved Haystack MRD, allowing commercial expansion across all 50 states. Quest Diagnostics also integrated selected cancer tests with Flatiron Health’s OncoEMR Molecular Profiling Integration platform. A pilot program with American Oncology Network is expected to support a broader rollout to Flatiron’s 4,700 clinicians and other providers later in 2026.
Strategic Imperative to Drive Operational Excellence: Quest Diagnostics’ Invigorate program now targets 3% annual cost savings and productivity improvements. The company is using automation and AI across laboratory and administrative processes to offset labor, benefit and reimbursement pressures while improving service quality. During the second quarter, Quest Diagnostics expanded AI-enabled cervical cancer screening and front-end specimen-processing automation to additional laboratories. It also launched IntelliDraw to guide specimen collection at physician offices and plans to introduce an AI-based supply tool at patient service centers. Project Nova remains a multi-year effort to transform order-to-cash processes, with higher spending expected in the second half of 2026 and the first implementation wave planned for fall 2027.
What Ails DGX?Unstable Reimbursement and Cost Backdrop: Quest Diagnostics remains exposed to changes in government reimbursement, health policy and payer bargaining power. Management continues to assume a 30-basis-point revenue impact in 2026 from the expiration of enhanced Affordable Care Act exchange subsidies. Exchange requisitions were down about 8%, although higher tests per requisition and payer mix kept related revenues roughly flat through the second quarter. A larger second-half impact remains possible.
Cost inflation also limits margin conversion. Second-quarter cost of services increased 10.9% year over year, while adjusted operating margin declined 40 basis points to 16.5%. Project Nova, the lower-margin Corewell and Fresenius mix and supplemental deferred compensation reduced the quarterly margin by a combined 70 basis points.
Elevated Debt Level: Quest Diagnostics’ leverage remains a concern despite better near-term liquidity. As of June 30, 2026, long-term debt was $5.63 billion, and cash and cash equivalents totaled $626 million. Interest expense was $126 million in the first half. Elevated debt could constrain financial flexibility as the company continues investing in acquisitions, automation and Project Nova.
DGX Stock Estimate TrendThe Zacks Consensus Estimate for Quest Diagnostics’ 2026 earnings per share (EPS) has increased 11.2% to $11.15 in the past 60 days.
The consensus estimate for the company’s 2026 revenues is pegged at $12.01 billion. This suggests 8.9% growth from the year-ago reported number.
Other Key PicksSome other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 22.3% compared to the industry’s 0.2% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 30.7% compared to the industry’s 0.2% growth over the past year.
Teleflex, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 1.6% compared with the industry’s 0.2% growth over the past year.
Aplikace Apple Health letos umožní uživatelům v USA objednat laboratorní testy Quest Diagnostics přímo v aplikaci. Panel s více než 50 biomarkery bude stát 119 USD.
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app
, /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.
"By embedding the Quest lab testing experience within the Apple Health app, we are making testing simpler, smarter and more available to people who want to connect biomarker and biometric insights to own their health," said Richard Adams, Senior Vice President and General Manager, Consumer, Quest Diagnostics. "This integration will help bridge the gap between clinical and consumer health and serve the growing interest in preventive health and wellness."
The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function. The panel also includes biometric readings that measure blood pressure, height, weight, and waist and hip circumferences, which may provide additional insights into metabolic health.
Users can purchase and schedule their blood draw and biometric readings at one of Quest's approximately 2,000 patient service centers in the United States for $119.
Shortly after testing, lab results will appear within the Apple Health app. Quest collaborates with third-party providers to review and approve all test orders and, at the user's request, discuss test results and next steps for no additional charge.
Chronic health conditions, such as heart disease and diabetes, affect as many as three in four American adults, yet can often be prevented if acted upon in early stages, according to the U.S. Centers for Disease Control and Prevention. Biomarker laboratory testing can identify early, asymptomatic signals of several chronic conditions, empowering individuals to make behavioral changes to reduce disease risk.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
Akcie Quest Diagnostics během úterního obchodování vystoupily na nové 52týdenní maximum 246,00 USD. Firma zároveň oznámila EPS 3,12 USD a tržby 3,04 miliardy USD, obojí nad odhady.
Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $246.00 and last traded at $243.9570, with a volume of 837684 shares changing hands. The stock had previously closed at $244.39.
Analyst Upgrades and Downgrades A number of brokerages have issued reports on DGX. Wall Street Zen raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 28th. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, August 12th. Truist Financial increased their price objective on shares of Quest Diagnostics from $225.00 to $250.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Mizuho raised their target price on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Robert W. Baird boosted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $235.31.
Read Our Latest Analysis on Quest Diagnostics
Quest Diagnostics Price Performance The company has a market cap of $26.93 billion, a price-to-earnings ratio of 25.90, a P/E/G ratio of 2.25 and a beta of 0.56. The company’s 50-day simple moving average is $220.20 and its 200-day simple moving average is $205.70. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.
Quest Diagnostics Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.
Insider Activity In related news, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,747 shares of company stock worth $3,947,088 over the last ninety days. Corporate insiders own 0.88% of the company’s stock.
Hedge Funds Weigh In On Quest Diagnostics Institutional investors have recently made changes to their positions in the business. Key Financial Inc grew its stake in Quest Diagnostics by 1,728.6% in the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Quest Diagnostics during the second quarter valued at approximately $29,000. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the fourth quarter valued at approximately $25,000. Sittner & Nelson LLC bought a new position in Quest Diagnostics during the 4th quarter worth approximately $29,000. Finally, DV Equities LLC bought a new position in Quest Diagnostics during the 4th quarter worth approximately $27,000. 88.06% of the stock is owned by institutional investors and hedge funds.
(Get Free Report)
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Recommended Stories Five stocks we like better than Quest Diagnostics Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Artia Global Partners LP ve 2. čtvrtletí koupila nový podíl v Quest Diagnostics za zhruba 13,8 milionu USD. Fond nyní drží 65 122 akcií, tedy 0,06 % společnosti.
Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company’s stock, valued at approximately $13,803,000. Quest Diagnostics comprises approximately 2.5% of Artia Global Partners LP’s holdings, making the stock its 12th largest holding. Artia Global Partners LP owned 0.06% of Quest Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Key Financial Inc boosted its position in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 121 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Quest Diagnostics during the 2nd quarter valued at $29,000. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the 4th quarter valued at $25,000. Sittner & Nelson LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $27,000. Institutional investors own 88.06% of the company’s stock.
Quest Diagnostics Price Performance NYSE:DGX opened at $244.78 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The company has a fifty day moving average price of $222.01 and a 200 day moving average price of $206.46. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $246.00. The stock has a market cap of $27.02 billion, a P/E ratio of 25.99, a PEG ratio of 2.25 and a beta of 0.56.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year. Quest Diagnostics Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.
Insiders Place Their Bets In related news, SVP Mark E. Delaney sold 1,600 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is currently owned by insiders.
Analyst Ratings Changes Several brokerages recently issued reports on DGX. Mizuho increased their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. UBS Group lifted their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Barclays raised their price target on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average target price of $235.31.
Check Out Our Latest Analysis on Quest Diagnostics
Quest Diagnostics Company Profile (Free Report)
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Further Reading Five stocks we like better than Quest Diagnostics Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Bank OZK ve 2. čtvrtletí získala novou pozici v Quest Diagnostics za zhruba 3,247 mil. USD. Firma zároveň oznámila čtvrtletní EPS 3,12 USD, nad odhadem analytiků 2,82 USD.
Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,322 shares of the medical research company’s stock, valued at approximately $3,247,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Quest Diagnostics in the second quarter valued at $1,965,923,000. Bank of America Corp DE bought a new stake in Quest Diagnostics in the second quarter worth about $410,151,000. Norges Bank acquired a new stake in Quest Diagnostics in the 4th quarter valued at about $229,522,000. Boston Partners boosted its position in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after purchasing an additional 997,033 shares in the last quarter. Finally, EdgePoint Investment Group Inc. grew its stake in shares of Quest Diagnostics by 95.5% in the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock worth $288,246,000 after purchasing an additional 811,320 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In Several research firms recently commented on DGX. Argus set a $260.00 target price on shares of Quest Diagnostics in a research note on Wednesday, July 29th. Barclays upped their price target on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Truist Financial increased their price objective on Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research report on Friday, July 24th. UBS Group raised their price objective on Quest Diagnostics from $220.00 to $232.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. boosted their target price on Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Moderate Buy” and an average target price of $235.31.
Read Our Latest Research Report on DGX Insider Buying and Selling In related news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer owned 132,423 shares in the company, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 19,747 shares of company stock worth $3,947,088. 0.88% of the stock is owned by company insiders.
Quest Diagnostics Stock Performance Shares of Quest Diagnostics stock opened at $244.48 on Friday. The stock has a market cap of $26.98 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 2.26 and a beta of 0.56. The business has a fifty day simple moving average of $223.00 and a 200-day simple moving average of $206.84. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $247.19.
Quest Diagnostics (NYSE:DGX – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the prior year, the business earned $2.62 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.
Quest Diagnostics Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 36.52%.
Quest Diagnostics Profile (Free Report)
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
See Also Five stocks we like better than Quest Diagnostics Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
Quest Diagnostics rozšíří portfolio AD-Detect o krevní test Roche pTau217 schválený FDA pro posouzení Alzheimerovy patologie. Zároveň spustí nový vícebiomarkerový test s 10% mírou neurčitých výsledků.
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients
Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight
, /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
Adding the FDA-cleared Elecsys pTau217 test to the AD-Detect™ portfolio
Earlier today, Roche announced that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, making it the first and only FDA-cleared single-assay, single-biomarker blood biomarker test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings. Quest provides a comprehensive menu of blood-based Alzheimer's biomarker tests under the AD-Detect™ brand name. Quest plans to introduce an AD-Detect-branded laboratory test service based on the FDA-cleared Elecsys® pTau217 assay to physicians and clinical trials collaborators nationwide in the fourth quarter of this year. Quest also plans to incorporate the Roche test in future AD-Detect panels in 2027.
"Blood-based biomarker testing has rapidly set a new standard of care for guiding treatment and diagnosis decisions for Alzheimer's disease," said Michael K. Racke, MD, a board-certified neurologist and senior medical director, neurology, Quest Diagnostics. "As one of the pioneers in this field, Quest is constantly looking to add new innovations, both our own and from our collaborators, to our extensive AD-Detect portfolio so that physicians and patients can make the most informed care decisions. As a long-time collaborator with Roche, we look forward to adding the Elecsys® pTau217 to our AD-Detect portfolio, which will give physicians across the U.S. ready access to this important biomarker test."
New AD-Detect multi-biomarker panel with 10% indeterminate rate
Separate from the FDA clearance of the Roche pTau217 test, Quest also announced today it will launch its newest AD-Detect test innovation, AD-Detect® ABeta 42/40, p-tau217, and ApoE Evaluation, lab-developed test for physicians and clinical trials collaborators nationwide at the end of this month. The test provides a score predicting the likelihood of Alzheimer's pathology based on results of pTau217 using a third party in vitro diagnostic as well as results of amyloid beta 42/40 and the APOE isoform (a genetic risk marker) using Quest's highly sensitive mass spectrometry method.
Research published in Neurology® Clinical Practice, a publication of the American Academy of Neurology, demonstrates that the new test aligns with guidelines from the Alzheimer Association, which state that blood-based tests that achieve sensitivity and specificity of approximately 90% in the intended use population in specialist settings may be used to confirm a diagnosis of Alzheimer's disease and aid clinical decisions without the need for additional testing. The same research also found that the new test achieved an indeterminate rate of 10%, compared to the 15%-20% rate recommended by the Global CEO Initiative on Alzheimer's Disease (CEOi) for a typical clinical population.
"Quest's extensive research demonstrates that blood-based biomarker testing that includes multiple biomarkers may be more sensitive and specific for Alzheimer's pathology and produces a lower rate of indeterminates compared to the same tests performed individually," said Amanda Backner, executive director and general manager, neurology, Quest Diagnostics.
With a physician's order, patients may conveniently provide a blood draw for testing for any AD-Detect test through Quest's patient service center network of approximately 2,000 locations in the U.S., as well as from Quest phlebotomists in physician offices and mobile phlebotomy services.
While positron emission tomography-computed tomography (PET-CT) scan and cerebrospinal fluid (CSF) testing are well established methods for aiding the diagnosis of Alzheimer's disease, may be costly, invasive and difficult to access outside specialty centers. In a study recently published in the Journal of Prevention of Alzheimer's Disease, Quest researchers determined that blood-based biomarker testing was a more efficient and cost-effective method of assessing Alzheimer's pathology in patients with cognitive decline than amyloid PET scans.
For more information on Quest AD-Detect, visit www.QuestForTheCure.com.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
Quest Diagnostics ve 2. čtvrtletí zaznamenala dvouciferný růst tržeb v nemocničním segmentu a v několika oblastech Advanced Diagnostics. Zároveň cílí na 3% roční úspory nákladů v rámci programu Invigorate kvůli zadlužení a tlaku na úhrady.
Key Takeaways Quest Diagnostics is seeing strong growth in physician, hospital and consumer channels.DGX's Advanced Diagnostics delivered double-digit growth in several clinical areas in the second quarter.Quest Diagnostics targets 3% annual cost savings as debt and reimbursement pressures weigh on results. Quest Diagnostics (DGX - Free Report) is well-poised to grow in the coming quarters owing to its solid growth momentum in the physician, hospital and consumer channels. Broader adoption of the company’s Advanced Diagnostics offerings, across five key clinical areas, also supports the growth outlook. Further, Quest Diagnostics continues to use automation and AI to improve the quality and productivity of its operations.Still, elevated debt and ongoing uncertainty around reimbursement and costs could weigh on results.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 33.9% compared with the industry’s 19.4% growth and the S&P 500 Composite’s 21.5% rise.
The renowned provider of diagnostic information services has a market capitalization of $26.68 billion. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.77%.
Factors Favoring DGXGrowth Momentum in the Base Business: Quest Diagnostics continues to address the needs of physicians, hospitals and consumers through broader access, clinical innovation and offering more integrated solutions. In the second quarter of 2026, physician channel revenues increased in the high single-digit range, supported by new customer wins, higher business with existing customers and growth in regions where the company expanded health plan access and completed acquisitions. The Fresenius Medical Care collaboration is also broadening Quest Diagnostics’ capabilities in kidney care.
Hospital channel revenues grew at a double-digit rate, primarily from Co-Lab Solutions with Corewell Health. Reference-testing revenues increased from both the first quarter and the prior-year period. The consumer-testing platform, QuestHealth.com, continued to generate revenue growth, supported by demand for wellness panels and newer services such as thyroid testing. The platform is also attracting consumer, wearable and wellness partners through flexible technology integration.
Image Source: Zacks Investment Research
Strong Potential of Advanced Diagnostics: Quest Diagnostics is expanding advanced diagnostics across cardiometabolic and endocrine, autoimmune, brain health, oncology and women’s and reproductive health. Several of these areas delivered double-digit revenue growth in the second quarter of 2026. Demand remained elevated for ApoB, Lp(a) and liver fibrosis tests, while the company continued to grow its analyzer solution for autoimmune disorders.
In brain health, the AD-Detect portfolio again produced double-digit growth. In oncology, New York State approved Haystack minimal residual disease, allowing commercial expansion across all 50 states. Quest Diagnostics also integrated selected cancer tests with Flatiron Health’s OncoEMR Molecular Profiling Integration platform. A pilot program with American Oncology Network is expected to support a broader rollout to Flatiron’s 4,700 clinicians and other providers later in 2026.
Strategic Imperative to Drive Operational Excellence: Quest Diagnostics’ Invigorate program now targets 3% annual cost savings and productivity improvements. The company is using automation and AI across laboratory and administrative processes to offset labor, benefit and reimbursement pressures while improving service quality. During the second quarter, Quest Diagnostics expanded AI-enabled cervical cancer screening and front-end specimen-processing automation to additional laboratories.
The company also launched IntelliDraw to guide specimen collection at physician offices and plans to introduce an AI-based supply tool at patient service centers. Project Nova remains a multi-year effort to transform order-to-cash processes, with higher spending expected in the second half of 2026 and the first implementation wave planned for fall 2027.
What Ails DGX?Elevated Debt Level: As of June 30, 2026, the company’s long-term debt was $5.63 billion and cash and cash equivalents totaled $626 million. The current portion of long-term debt declined to $10 million after the company repaid $500 million of notes due in June and issued $500 million of 5.00% notes due in 2036. Interest expense totaled $126 million in the first half. Elevated debt could constrain financial flexibility as the company continues investing in acquisitions, automation and Project Nova.
Unstable Reimbursement and Cost Backdrop: Quest Diagnostics remains exposed to changes in government reimbursement, health policy and payer bargaining power. Management continues to assume a 30-basis-point (bps) revenue impact in 2026 from the expiration of enhanced Affordable Care Act exchange subsidies. Exchange requisitions were down about 8%, although higher tests per requisition and payer mix kept related revenues roughly flat through the second quarter. Second-quarter cost of services increased 10.9% year over year, while adjusted operating margin declined 40 bps to 16.5%.
DGX Stock Estimate TrendThe Zacks Consensus Estimate for Quest Diagnostics’ 2026 earnings per share (EPS) is projected to increase 13.2% to $11.15.
The consensus mark for 2026 revenues is pegged at $12.01 billion, suggesting 8.9% growth from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 37.1% against the industry’s 4.2% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 34.8% against the industry’s 4.2% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 4.3% against the industry’s 4.3% decline over the past year.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
Quest Diagnostics zvýšil výhled tržeb pro rok 2026 na 11,95–12,05 miliardy USD a upraveného EPS na 11,05–11,25 USD po lepších výsledcích za 2. čtvrtletí. Organický objem žádostí vzrostl o 13 %.
Key Takeaways Quest Diagnostics raised 2026 revenue and adjusted EPS guidance after a second-quarter beat. Organic requisition volume rose 13%, while revenue per requisition fell 2.8%, making volume the key driver.Lower-margin partnerships, Project Nova spending and fuel costs could slow margin expansion. Quest Diagnostics Incorporated (DGX - Free Report) raised its 2026 revenue and adjusted earnings guidance after second-quarter results topped expectations. The increase reflects faster testing demand across physician, hospital and consumer channels.
The outlook is improving, but the quality of the upside still matters. Investors must weigh durable organic volume growth against acquisition contributions, lower-margin partnerships and higher spending on operational projects.
Quest Lifts Revenue and Earnings GuidanceQuest now expects 2026 revenues of $11.95 billion to $12.05 billion, up from its prior range of $11.78 billion to $11.90 billion. The revised range implies growth of 8.3% to 9.2%.
Adjusted earnings are projected at $11.05-$11.25 per share, compared with the earlier $10.63-$10.83 range. The new midpoint stands above the Zacks Consensus Estimate of $11.11 per share at the time of the report.
Image Source: Zacks Investment Research
DGX Volume Growth Powers the Second-Quarter BeatSecond-quarter Revenues rose 10.2% to $3.04 billion, exceeding the consensus mark by 2.1%.
Total requisition volume climbed 13.1%, while organic requisition volume advanced 13%. Revenue per requisition fell 2.8%, showing that volume, rather than pricing, carried the quarter. Labcorp Holdings Inc. (LH - Free Report) , another major laboratory-services provider, competes with Quest across diagnostics and health-system relationships, keeping service quality and access central to share gains.
Per, the Zacks Consensus Estimate, revenues are pegged at 11.99 billion for 2026.
Image Source: Zacks Investment Research
Quest Partnerships Add Revenue and Mix PressureCorewell Health is expected to contribute about $250 million to 2026 revenues. The joint venture expands Quest’s hospital channel, while the acquired Fresenius Medical Care assets broaden its kidney-care testing capabilities.
Those additions improve scale but come with lower margins. DaVita Inc. (DVA - Free Report) , a comprehensive kidney-care provider, operates across the same broader kidney-health ecosystem that Quest is targeting through risk assessment, dialysis-related testing and post-transplant monitoring. Quest’s opportunity is meaningful, but integration discipline will determine how quickly revenue converts into profit.
In the past year, DGX shares have risen 35.2% compared with the industry’s 33.7% growth.
Image Source: Zacks Investment Research
DGX Spending Could Delay Margin PayoffProject Nova spending is expected to increase in the second half of 2026, and management also anticipates about $10 million in fuel-cost pressure for the year. Integration expenses and lower-margin partnership revenue add another layer of near-term dilution.
Second-quarter adjusted operating margin declined 40 basis points to 16.5%. Management still expects full-year margin expansion, supported by volume growth, Invigorate savings and less dilution from Corewell and Fresenius later in the year. That outcome depends on cost execution keeping pace with demand.
Quest Signals Back the Improved Earnings ViewThe raised outlook strengthens the earnings case, but the mix of organic growth, acquired revenues and spending remains important. Sustained requisition gains and productivity savings would make the upgrade more durable, while integration or cost slippage could limit margin expansion.
Quest currently carries a Zacks Rank #2 (Buy), which reflects favorable earnings estimate revision trends over the near term. The stock also has a Momentum Score of A and a VGM Score of A, while its Value Score and Growth Score are both B. The combination points to favorable momentum and balanced style characteristics, though the stock’s premium valuation and execution demands still warrant attention.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics ve 2. čtvrtletí zvýšila upravený zisk na akcii na 3,12 USD a tržby o 10,2 % na 3,04 mld. USD. Zároveň zvýšila výhled tržeb pro rok 2026 na 11,95–12,05 mld. USD a upraveného EPS na 11,05–11,25 USD.
Key Takeaways DGX posted adjusted EPS of $3.12 as revenues rose 10.2% and requisition volume climbed 13.1%. Quest Diagnostics raised 2026 revenue guidance to $11.95B-$12.05B and adjusted EPS to $11.05-$11.25. DGX's elevated valuation, $5.63B debt and lower operating margin leave less room for execution missteps. Quest Diagnostics Incorporated (DGX - Free Report) has rallied as earnings momentum improved, estimates moved higher and demand broadened across its testing platform.
The buy case is not one-sided. The stock’s advance has lifted valuation closer to its five-year high, while leverage, cost pressure and reimbursement uncertainty leave less room for execution missteps.
DGX Delivers a Strong Second-Quarter BeatQuest Diagnostics reported second-quarter 2026 adjusted earnings of $3.12 per share, up 19.1% year over year. The result surpassed the Zacks Consensus Estimate by 11%, extending a period of positive earnings momentum.
Revenues rose 10.2% year over year to $3.04 billion and beat the consensus mark by 2.1%. Growth was supported by a 13.1% increase in requisition volume, with Diagnostic Information Services benefiting from physician, hospital and consumer channels.
Physician channel revenues increased in the high single-digit range, helped by new customer wins, higher business with existing customers and expanded health plan access. Hospital revenues grew at a double-digit rate, while QuestHealth.com continued to see demand for wellness panels and newer services such as thyroid testing.
Quest Diagnostics Raises Its 2026 OutlookQuest Diagnostics now expects 2026 revenues of $11.95 billion to $12.05 billion, up from its prior range of $11.78 billion to $11.90 billion. The revised outlook implies revenue growth of 8.3-9.2%.
Adjusted earnings are projected at $11.05 to $11.25 per share, compared with the previous range of $10.63 to $10.83. The Zacks Consensus Estimate for 2026 earnings has also moved higher, with the current-year earnings estimate up 4.1% over the past four weeks.
The higher outlook reflects stronger testing demand and better expected earnings conversion. It also supports the case that Quest’s base business, acquisitions and advanced diagnostics portfolio are contributing to near-term growth.
DGX Valuation Leaves Less Room for ErrorValuation is the main counterweight after the share-price run. DGX trades at 20.34X forward 12-month earnings, above its five-year median of 16.16X and at the high end of its five-year range of 11.34X to 20.65X.
Image Source: Zacks Investment Research
Shares recently traded at $235.22, compared with a $252 price target. That target still points to positive potential, but the upside is moderate after gains of 24.4% in the past three months and 39.4% over the past year.
The stock also trades slightly above the S&P 500 on a forward earnings basis. Investors are paying for improved visibility, but the valuation leaves less cushion if volumes slow, costs rise or margin recovery takes longer.
Quest Diagnostics Faces Debt and Margin RisksQuest Diagnostics ended the second quarter with $626 million in cash and cash equivalents, while long-term debt stood at $5.63 billion. Elevated debt could limit flexibility as the company invests in acquisitions, automation and Project Nova.
Margin trends also require monitoring. Adjusted operating margin declined 40 basis points to 16.5% in the second quarter, as higher service costs, Project Nova spending, supplemental deferred compensation and the lower-margin Corewell and Fresenius mix weighed on profitability.
Reimbursement remains another pressure point. Management continues to assume a 30-basis-point 2026 revenue impact tied to the expiration of enhanced Affordable Care Act exchange subsidies, with a larger second-half effect still possible.
Labcorp Holdings Inc. (LH - Free Report) remains a relevant peer because it operates in the same diagnostics and laboratory services market where price, access, turnaround time and service quality matter. DaVita Inc. (DVA - Free Report) adds context for kidney-care exposure, an area where Quest has broadened capabilities through the Fresenius Medical Care collaboration.
Based on short-term price targets offered by 16 analysts, the average price target for Quest Diagnostics comes to $242.75, representing an increase of 3.2% from the last closing price.
Image Source: Zacks Investment Research
DGX Scores Favor Near-Term SelectivityDGX still has a constructive near-term profile. The stock currently carries a Zacks Rank #2 (Buy), which reflects favorable earnings estimate revision trends over the one-to-three-month horizon.
The Style Scores add nuance. DGX has a Momentum Score of A and a VGM Score of A, while its Value Score and Growth Score are both B. That mix points to solid overall characteristics, with momentum currently standing out more than the valuation margin of safety.
For investors, the stock remains worth watching, but selectivity is warranted. Earnings momentum, higher guidance and positive estimate revisions support the near-term case, while valuation, leverage and margin pressure argue against chasing the stock without regard to entry point.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Quest Diagnostics v roce 2026 sází na silnou poptávku po testování, pokročilou diagnostiku a partnerství. Ve 2. čtvrtletí vzrostly tržby od lékařů v horní části jednociferného pásma a nemocniční tržby dvouciferně.
Key Takeaways DGX is using broad testing demand, advanced diagnostics and partnerships to support 2026 growth. Physician revenues rose high single digits, while hospital revenues grew in the second quarter. DGX targets annual cost savings as AI, automation and Project Nova address labor and reimbursement woes. Quest Diagnostics Incorporated (DGX - Free Report) is combining broad testing demand, wider payer access, advanced diagnostics and partnership-led expansion to support revenue growth in 2026.
For investors, the key question is whether these drivers can keep lifting revenues while automation, artificial intelligence and cost programs protect profitability against reimbursement, integration and spending pressures.
Quest Diagnostics Builds on Broad-Based DemandQuest Diagnostics’ base business continues to benefit from physicians, hospitals and consumers. In the second quarter of 2026, physician-channel revenues increased in the high-single-digit range, supported by new customer wins, higher business from existing customers, acquisitions and growth in regions with expanded health plan access.
Hospital-channel revenues grew at a double-digit rate, mainly from Co-Lab Solutions with Corewell Health. QuestHealth.com also generated revenue growth, helped by demand for wellness panels, newer thyroid testing services and technology integrations with consumer, wearable and wellness partners.
In the past year, DGX shares have gained 39.4% compared with the industry’s 33.5% growth.
Image Source: Zacks Investment Research
Labcorp Holdings Inc. (LH - Free Report) remains a relevant comparison point because it competes in laboratory services and broader diagnostics. Quest’s growth signals therefore matter not only for DGX holders but also for investors tracking how scale and access affect the testing market.
DGX Expands Advanced Diagnostics Across Key AreasAdvanced Diagnostics remains one of Quest’s clearer growth engines. The company is expanding across cardiometabolic and endocrine health, autoimmune disorders, brain health, oncology, and women’s and reproductive health, with several targeted areas delivering double-digit revenue growth in the second quarter of 2026.
Demand remained elevated for ApoB, Lp(a) and liver fibrosis tests. The AD-Detect brain-health portfolio again delivered double-digit growth, while New York State approval of Haystack MRD enabled commercial expansion across all 50 states.
Quest Diagnostics Uses Deals to Extend ReachQuest continues to use acquisitions and joint ventures to expand geographic reach, health plan access and specialized testing capabilities. The company targets 1%-2% annual revenue growth from acquisitions, with an emphasis on hospital outreach assets and independent laboratories.
The Corewell Health laboratory venture is a central example. Formed in January 2026, the Michigan joint venture is owned 51% by Quest and 49% by Corewell, is expected to contribute about $250 million to 2026 revenues and is scheduled to launch a new joint venture laboratory in early 2027.
DaVita Inc. (DVA - Free Report) is another healthcare-services peer tied to the broader kidney-care ecosystem. Quest’s acquired Fresenius Medical Care testing assets and kidney-care collaboration underscore how lab services can deepen ties with providers serving chronic disease populations.
DGX Targets Efficiency Through AI and AutomationQuest’s Invigorate program now targets 3% annual cost savings and productivity improvements. The effort is designed to offset labor, benefit and reimbursement pressures while improving service quality across laboratory and administrative workflows.
The company expanded AI-enabled cervical cancer screening and front-end specimen-processing automation to additional laboratories in the second quarter. It also launched IntelliDraw for specimen collection at physician offices and plans an AI-based supply tool at patient service centers, while Project Nova remains a multiyear order-to-cash transformation with the first implementation wave planned for fall 2027.
In the past 30 days, estimates for Quest Diagnostics’ 2026 earnings have moved north by 3.7%.
Image Source: Zacks Investment Research
Quest Diagnostics Signals Support a Balanced ViewThe bottom line is that Quest has several visible growth drivers, but the case is not one-sided. Broad demand, advanced diagnostics and partnerships support revenues, while elevated debt, reimbursement uncertainty, cost inflation and margin execution remain important risks.
DGX currently carries a Zacks Rank #2 (Buy), supported by favorable estimate-revision trends. The stock also has a Momentum Score of A, Value Score of B, Growth Score of B and VGM Score of A, a combination that points to favorable short-term characteristics across price action, valuation and growth.
The Style Scores are designed to complement the Zacks Rank, not replace it. For DGX, the Rank and scores support a constructive near-term view, while the longer-term outlook remains more balanced because execution around Project Nova, partnership margins and reimbursement pressure still matters.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Quest Diagnostics za minulý týden vzrostl o více než 8 % poté, co zvýšil celoroční výhled tržeb a zisku. Ve 2. čtvrtletí tržby stouply o 10 % na 3 miliardy USD a upravený zisk na akcii o 19 % na 3,12 USD.
Shares of Quest Diagnostics (DGX -0.02%) rose more than 8% last week after the medical testing leader boosted its full-year sales and profit forecast.
Image source: Getty Images.
Healthy Q2 results Quest's revenue jumped 10% year over year to $3 billion in the second quarter.
This growth was driven in part by the Quest's partnerships with Corewell Health, a non-profit healthcare system in Michigan, and Fresenius Medical Care, a leading provider of kidney dialysis and related services.
The healthcare giant also saw solid gains in its Questhealth.com direct-to-consumer business, as well as its wellness and wearables-related sales.
Today's Change
(
-0.02
%) $
-0.04
Current Price
$
227.86
At the same time, Quest's investments in automation technology and artificial intelligence (AI) are making its labs more efficient. That's helping to boost its profit margins.
All told, Quest's adjusted earnings leaped 19% to $3.12 per share.
Healthier living trends bode well for Quest's long-term growth These robust results prompted Quest to lift its full-year financial outlook. Management now projects revenue of roughly $12 billion and adjusted earnings per share of $11.05 to $11.25.
With a vast lab network that serves half the physicians and hospitals in the U.S., Quest plays a vital role in providing potentially life-saving health insights to millions of people every year.
With more people becoming more health-conscious, demand for Quest's medical testing services is set to climb in the years ahead.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Quest Diagnostics. The Motley Fool has a disclosure policy.
Quest Diagnostics ve 2. čtvrtletí zvýšil tržby o 10,2 % na 3,04 miliardy USD a upravený EPS o 19,1 % na 3,12 USD. Firma zároveň zvedla celoroční výhled tržeb a EPS pro rok 2026.
Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025 Full year 2026 revenues now expected to be between $11.95 billion and $12.05 billion Full year 2026 reported diluted EPS now expected to be between $9.97 and $10.17; and adjusted diluted EPS expected to be between $11.05 and $11.25 , /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2026.
"Our robust top- and bottom-line growth in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate paths for better health," said Jim Davis, Chairman, CEO and President. "Revenues increased by over 10%, almost all from organic revenue growth across our physician, hospital and consumer channels, and adjusted diluted EPS grew over 19%. With strong growth and sustained demand for our diagnostic insights, we are again raising our full year guidance."
Recent Highlights:
Serving Customers and Delivering Innovations
Continued to advance our Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan and developed new capabilities in kidney care through our collaboration with Fresenius Medical Care in the United States. Generated robust revenue growth through questhealth.com and our consumer, wearable and wellness partners. Grew revenues by double-digits in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer's disease and advanced cardiometabolic and endocrine tests, including liver fibrosis testing. Granted New York State approval for our Haystack MRD® test and became the largest reference lab to utilize Flatiron Health's OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests, including Haystack MRD, starting with a pilot with American Oncology Network (AON). Driving Operational Excellence
In the lab, extended automation solutions to improve quality and productivity in cervical cancer screening and front-end specimen processing to additional labs. Outside the lab, launched IntelliDraw™ to guide clinical staff of our physician customers through specimen collection, to enhance quality and the service experience.
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
Change
2026
2025
Change
(dollars in millions, except per share data)
Reported:
Net revenues
$ 3,043
$ 2,761
10.2 %
$ 5,938
$ 5,413
9.7 %
Diagnostic Information Services
revenues
$ 2,978
$ 2,699
10.3 %
$ 5,810
$ 5,288
9.9 %
Revenue per requisition
(2.8) %
(2.1) %
Requisition volume
13.1 %
12.0 %
Organic requisition volume
13.0 %
11.9 %
Operating income (a)
$ 459
$ 438
4.6 %
$ 858
$ 784
9.4 %
Operating income as a percentage of net
revenues (a)
15.1 %
15.9 %
(0.8) %
14.4 %
14.5 %
(0.1) %
Net income attributable to Quest
Diagnostics (a)
$ 320
$ 282
13.4 %
$ 572
$ 502
13.9 %
Diluted EPS (a)
$ 2.84
$ 2.47
15.0 %
$ 5.08
$ 4.41
15.2 %
Cash provided by operations
$ 597
$ 544
9.7 %
$ 875
$ 858
1.9 %
Capital expenditures
$ 138
$ 108
27.0 %
$ 252
$ 225
12.1 %
Adjusted (a):
Operating income
$ 502
$ 466
7.8 %
$ 949
$ 872
8.8 %
Operating income as a percentage of net
revenues
16.5 %
16.9 %
(0.4) %
16.0 %
16.1 %
(0.1) %
Net income attributable to Quest
Diagnostics
$ 350
$ 298
17.3 %
$ 631
$ 549
14.9 %
Diluted EPS
$ 3.12
$ 2.62
19.1 %
$ 5.62
$ 4.83
16.4 %
(a)
For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.
Updated Guidance for Full Year 2026
The company updates its full year 2026 guidance as follows:
Updated Guidance
Prior Guidance
Low
High
Low
High
Net revenues
$11.95 billion
$12.05 billion
$11.78 billion
$11.90 billion
Net revenues increase
8.3 %
9.2 %
6.8 %
7.8 %
Reported diluted EPS
$9.97
$10.17
$9.58
$9.78
Adjusted diluted EPS
$11.05
$11.25
$10.63
$10.83
Cash provided by operations
Approximately $1.80 billion
Approximately $1.75 billion
Capital expenditures
Approximately $550 million
Approximately $550 million
Based on the favorable resolution of various tax contingencies in the second quarter, the full year adjusted effective tax rate is expected to be consistent with 2025.
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments and other items.
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on July 23, 2026 until midnight Eastern Time on August 6, 2026, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
Net revenues
$ 3,043
$ 2,761
$ 5,938
$ 5,413
Operating costs and expenses and other operating income:
Cost of services
2,016
1,818
3,969
3,607
Selling, general and administrative
529
486
1,033
962
Amortization of intangible assets
38
39
75
78
Other operating expense (income), net
1
(20)
3
(18)
Total operating costs and expenses, net
2,584
2,323
5,080
4,629
Operating income
459
438
858
784
Other income (expense):
Interest expense, net
(63)
(67)
(126)
(134)
Other income, net
16
13
14
10
Total non-operating expense, net
(47)
(54)
(112)
(124)
Income before income taxes and equity in earnings of equity method
investees
412
384
746
660
Income tax expense
(88)
(97)
(162)
(156)
Equity in earnings of equity method investees, net of taxes
10
9
14
27
Net income
334
296
598
531
Less: Net income attributable to noncontrolling interests
14
14
26
29
Net income attributable to Quest Diagnostics
$ 320
$ 282
$ 572
$ 502
Earnings per share attributable to Quest Diagnostics' common
stockholders:
Basic
$ 2.88
$ 2.51
$ 5.15
$ 4.48
Diluted
$ 2.84
$ 2.47
$ 5.08
$ 4.41
Weighted average common shares outstanding:
Basic
111
112
110
112
Diluted
112
113
112
113
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
June 30, 2026 and December 31, 2025
(in millions, except per share data)
(unaudited)
June 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$ 626
$ 420
Accounts receivable, net
1,666
1,408
Inventories
233
189
Prepaid expenses and other current assets
319
361
Total current assets
2,844
2,378
Property, plant and equipment, net
2,219
2,203
Operating lease right-of-use assets
678
657
Goodwill
9,112
8,945
Intangible assets, net
1,672
1,636
Investments in equity method investees
137
136
Other assets
277
270
Total assets
$ 16,939
$ 16,225
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses
$ 1,598
$ 1,600
Current portion of long-term debt
10
504
Current portion of long-term operating lease liabilities
180
174
Total current liabilities
1,788
2,278
Long-term debt
5,632
5,167
Long-term operating lease liabilities
561
537
Other liabilities
1,059
957
Redeemable noncontrolling interest
80
80
Stockholders' equity:
Quest Diagnostics stockholders' equity:
Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2026 and
December 31, 2025; 162 shares issued as of both June 30, 2026 and December 31, 2025
2
2
Additional paid-in capital
2,374
2,381
Retained earnings
10,374
9,994
Accumulated other comprehensive loss
(62)
(27)
Treasury stock, at cost; 52 shares as of both June 30, 2026 and December 31, 2025
(5,172)
(5,180)
Total Quest Diagnostics stockholders' equity
7,516
7,170
Noncontrolling interests
303
36
Total stockholders' equity
7,819
7,206
Total liabilities and stockholders' equity
$ 16,939
$ 16,225
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2026 and 2025
(in millions)
(unaudited)
Six Months Ended June 30,
2026
2025
Cash flows from operating activities:
Net income
$ 598
$ 531
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
293
283
Provision for credit losses
3
2
Deferred income tax expense
46
8
Stock-based compensation expense
43
43
Other, net
14
26
Changes in operating assets and liabilities:
Accounts receivable
(259)
(115)
Accounts payable and accrued expenses
130
(11)
Income taxes payable
4
9
Other assets and liabilities, net
3
82
Net cash provided by operating activities
875
858
Cash flows from investing activities:
Business acquisitions, net of cash acquired
(38)
(17)
Capital expenditures
(252)
(225)
Other investing activities, net
4
3
Net cash used in investing activities
(286)
(239)
Cash flows from financing activities:
Proceeds from borrowings
494
400
Repayments of debt
(501)
(1,001)
Purchases of treasury stock
(102)
—
Exercise of stock options
81
42
Employee payroll tax withholdings on stock issued under stock-based compensation plans
(38)
(42)
Dividends paid
(184)
(174)
Distributions to noncontrolling interest partners
(22)
(29)
Other financing activities, net
(109)
(50)
Net cash used in financing activities
(381)
(854)
Effect of exchange rate changes on cash and cash equivalents and restricted cash
(2)
5
Net change in cash and cash equivalents and restricted cash
206
(230)
Cash and cash equivalents and restricted cash, beginning of period
420
549
Cash and cash equivalents and restricted cash, end of period
$ 626
$ 319
Cash paid during the period for:
Interest
$ 129
$ 145
Income taxes
$ 104
$ 110
Notes to Financial Tables
1) The computation of basic and diluted earnings per common share is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
(in millions, except per share data)
Amounts attributable to Quest Diagnostics' common stockholders:
Net income attributable to Quest Diagnostics
$ 320
$ 282
$ 572
$ 502
Less: earnings allocated to participating securities
1
1
2
2
Earnings available to Quest Diagnostics' common stockholders - basic and
diluted
$ 319
$ 281
$ 570
$ 500
Weighted average common shares outstanding - basic
111
112
110
112
Effect of dilutive securities:
Stock options and performance share units
1
1
2
1
Weighted average common shares outstanding - diluted
112
113
112
113
Earnings per share attributable to Quest Diagnostics' common
stockholders:
Basic
$ 2.88
$ 2.51
$ 5.15
$ 4.48
Diluted
$ 2.84
$ 2.47
$ 5.08
$ 4.41
2) The following tables reconcile reported GAAP results to non-GAAP adjusted results:
Three Months Ended June 30, 2026
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 459
15.1 %
$ (88)
$ 10
$ 320
$ 2.84
Restructuring and
integration charges (a)
4
0.2
(1)
—
3
0.04
Other charges (b)
1
—
1
—
2
0.02
Gains and losses on
investments (c)
—
—
—
(1)
(1)
(0.01)
Amortization expense
38
1.2
(10)
—
28
0.25
ETB
—
—
(2)
—
(2)
(0.02)
As adjusted
$ 502
16.5 %
$ (100)
$ 9
$ 350
$ 3.12
Six Months Ended June 30, 2026
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 858
14.4 %
$ (162)
$ 14
$ 572
$ 5.08
Restructuring and
integration charges (a)
11
0.2
(3)
—
8
0.08
Other charges (b)
5
0.1
—
—
5
0.05
Gains and losses on
investments (c)
—
—
(2)
6
4
0.04
Amortization expense
75
1.3
(19)
—
56
0.50
ETB
—
—
(14)
—
(14)
(0.13)
As adjusted
$ 949
16.0 %
$ (200)
$ 20
$ 631
$ 5.62
Three Months Ended June 30, 2025
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 438
15.9 %
$ (97)
$ 9
$ 282
$ 2.47
Restructuring and
integration charges (a)
7
0.3
(2)
—
5
0.04
Other charges (b)
28
1.0
(6)
—
22
0.19
Gains and losses on
investments (c)
—
—
1
(1)
(2)
(0.01)
Other gains (d)
(46)
(1.7)
12
—
(34)
(0.30)
Amortization expense
39
1.4
(11)
—
28
0.25
ETB
—
—
(3)
—
(3)
(0.02)
As adjusted
$ 466
16.9 %
$ (106)
$ 8
$ 298
$ 2.62
Six Months Ended June 30, 2025
(dollars in millions, except per share data)
Operating
income
Operating
income as a
percentage of
net revenues
Income tax
expense (e)
Equity in
earnings of
equity method
investees, net
of taxes
Net income
attributable to
Quest
Diagnostics
Diluted EPS
As reported
$ 784
14.5 %
$ (156)
$ 27
$ 502
$ 4.41
Restructuring and
integration charges (a)
26
0.5
(7)
—
19
0.17
Other charges (b)
30
0.6
(6)
—
24
0.21
Gains and losses on
investments (c)
—
—
1
(1)
(2)
(0.01)
Other gains (d)
(46)
(0.9)
14
(8)
(40)
(0.36)
Amortization expense
78
1.4
(20)
—
58
0.51
ETB
—
—
(12)
—
(12)
(0.10)
As adjusted
$ 872
16.1 %
$ (186)
$ 18
$ 549
$ 4.83
(a)
For each of the three and six months ended June 30, 2026 and 2025, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:
Three Months Ended
June 30,
Six Months Ended
June 30,
2026
2025
2026
2025
(dollars in millions)
Cost of services
$ 1
$ 1
$ 2
$ 7
Selling, general and administrative
3
6
9
19
Operating income
$ 4
$ 7
$ 11
$ 26
(b)
The three and six months ended June 30, 2026 and 2025 include losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions, recorded in other operating expense (income), net. Additionally, for both the three and six months ended June 30, 2025, the pre-tax impact primarily represents a $24 million impairment charge on certain long-lived assets related to the exit of a business, recorded in other operating expense (income), net.
(c)
For all periods presented, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, principally recorded in equity in earnings of equity method investees, net of taxes, and other income, net.
(d)
The three and six months ended June 30, 2025 include a $46 million pre-tax gain, recorded in other operating expense (income), net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act associated with the retention of employees. Additionally, the six months ended June 30, 2025 includes an $8 million gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease.
(e)
For restructuring and integration charges, other gains/charges, gains and losses on investments, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2026 and 2025. No income tax impact was recorded on losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions.
3)
For both the three and six months ended June 30, 2026, we repurchased 0.5 million shares of our common stock for $100 million. As of June 30, 2026, $1.3 billion remained available under our share repurchase authorization.
4)
The outlook for adjusted diluted EPS represents management's estimates for the full year 2026 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2026. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2026 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS:
Low
High
Diluted EPS
$ 9.97
$ 10.17
Restructuring and integration charges (a)
0.14
0.14
Amortization expense (b)
0.99
0.99
Other charges (c)
0.10
0.10
Gains and losses on investments (d)
0.04
0.04
ETB
(0.19)
(0.19)
Adjusted diluted EPS
$ 11.05
$ 11.25
(a)
Represents estimated pre-tax charges of $21 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.
(b)
Represents estimated pre-tax amortization expenses of $149 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%.
(c)
Principally represents estimated pre-tax net losses of $9 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Such estimate is subject to the risks and uncertainties discussed in the "Forward Looking Statements" section above. No income tax benefits are recorded on the changes associated with the contingent consideration accrual.
(d)
Income tax impacts were calculated using a combined statutory income tax rate of 25.5%.
Quest Diagnostics očekává za 2. čtvrtletí tržby 2,98 miliardy USD, což je meziročně o 7,9 % více. Růst má podpořit silná poptávka ve fyzickém, nemocničním i spotřebitelském kanálu.
Key Takeaways Quest Diagnostics is expected to post Q2 revenues of $2.98 billion, up 7.9% from the year-ago level. DGX may benefit from physician, hospital and consumer channel growth, including ESRD and Co-Lab expansion. Quest Diagnostics expects advanced diagnostics, Quest AI Companion and Invigorate synergies to aid results. Quest Diagnostics (DGX - Free Report) is set to release second-quarter 2026 results on July 23, before the market opens.
In the last reported quarter, the renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.50, which surpassed the Zacks Consensus Estimate by 5.49%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.50%.
Q2 Estimates for DGXThe Zacks Consensus Estimate for revenues is pegged at $2.98 billion, indicating an increase of 7.9% from the year-ago reported figure.
The Zacks Consensus Estimate for the company’s EPS suggests a 7.3% rise to $2.81.
Estimate Revision Trend Ahead of DGX’s Q2 EarningsEstimates for Quest Diagnostics’ Q2 earnings have remained unchanged in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence DGX’s Q2 ResultsAs in the previous quarter, second-quarter 2026 revenues are expected to have been supported by broad-based demand for its clinical innovations, expansion into new clinical areas, and partnerships with leading healthcare and consumer health organizations.
In the physician channel, a key driver has likely been geographic expansion from greater health plan access, expanding the reach of Quest Diagnostics’ lab services. Enterprise accounts might have contributed additional revenues from new customer wins and expanded business. The company's entry into end-stage renal disease (ESRD), a new clinical area, is expected to have boosted revenues in the to-be-reported quarter.
Growth in the hospital channel may have been driven by Co-Lab solutions, which leverages the company’s lab and process management expertise to optimize quality and drive cost efficiencies. Early in 2026, DGX began scaling its Co-Lab solutions across all 21 hospitals of Corewell Health, its largest implementation to date. This is expected to have had a positive impact on revenues.
Quest Diagnostics Incorporated Price and EPS SurpriseIn the consumer channel, as in recent quarters, the company is likely to have generated strong revenue growth from both questhealth.com and its portfolio of leading consumer health collaborations. This growth is expected to have been driven by notable demand for its new solutions such as the Elite health profile and autoimmune and hormone tests.
In the second quarter of 2026, the company is likely to have maintained momentum in Advanced Diagnostics, which includes non-routine and specialized tests across advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health areas. Offerings such as the Quest AD-Detect blood test portfolio for Alzheimer's disease, the ANAlyzeR autoimmune solution and the new Flow Cytometry measurable residual disease (MRD) for Myeloma are expected to have supported growth.
The company is also leveraging artificial intelligence through the newly launched Quest AI Companion, which transforms complex biomarker data and reference ranges in test reports into clear, easy-to-understand language. Patients have engaged with Quest AI Companion approximately 350,000 times since its first-quarter launch, and we expect this momentum to have continued in the to-be-reported quarter. Additionally, operational efficiencies and cost synergies from the Invigorate initiative are likely to have supported Quest Diagnostics' operating performance.
What Our Model Unveils for DGXPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1. The company is expected to release second-quarter 2026 results soon.
In the trailing four quarters, HINGE delivered an average surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease 11.9% from the year-ago quarter’s figure.
Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.
NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.
West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.
Quest Diagnostics spouští pilotní integraci testů Haystack MRD a genomického profilování do systému OncoEMR od společnosti Flatiron Health. Po dokončení integrace získá přístup 4 700 kliniků napříč sítí 1 600 komunitních onkologických pracovišť v USA, včetně téměř 200 pracovišť AON.
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD
, /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from Flatiron Health, via a pilot program with American Oncology Network (AON) and other community oncology providers. Flatiron Health is a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology.
Quest is the largest clinical reference lab to integrate oncology tests in OncoEMR using the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature, which is designed to support the specialized test ordering requirements of comprehensive molecular tests. Once completed, the integration will enable 4,700 clinicians across the Flatiron network of 1,600 community-based cancer care locations in the United States to quickly access the Quest services.
"At Flatiron, we're focused on helping oncology teams get the answers they need to deliver the best possible care," said Quincy Weatherspoon, Chief Network Officer, US Point of Care, Flatiron Health. "By integrating Quest's advanced oncology services directly into existing workflows, we're making it easier for physicians to access critical testing insights without adding complexity to their day. This collaboration helps reduce administrative burden so clinicians can spend less time navigating processes and more time focused on caring for patients with cancer."
Molecular oncology testing often involves dozens or even hundreds of individual genetic biomarkers, which can complicate ordering workflows and producing long, complex results reports. The use of OncoEMR MPI will enable providers to set up accounts for Quest services faster, order tests with fewer steps, and receive easy-to-understand reports within their daily EHR workflows.
Select providers can now order and receive results from Quest using the OncoEMR MPI capability as part of a pilot program. Among the pilot customers is American Oncology Network (AON), a leader in community oncology with more than 350 providers practicing across 21 states. Nearly 200 AON sites now have access to OncoEMR MPI and can use it to order the Quest tests. Quest plans to launch the full OncoEMR MPI integration to providers nationwide in the second half of the year.
"At AON, our aim is to provide comprehensive support, ancillary services and practice management benefits to help community physicians to make cancer care better. Empowering them to use OncoEMR MPI via Quest Diagnostics is an important step in that mission," said Dr. Brian Mulherin, Medical Director at AON. "Under this arrangement, our rapidly growing network of physicians can quickly and easily order Quest's innovative cancer tests, such as Haystack MRD, to help guide patient care."
Providers in the pilot now have access to some of Quest's most innovative cancer tests, including Haystack MRD, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test for solid tumor cancers. In addition, the company's Comprehensive Genomic Profiling portfolio includes several panels that use advanced sequencing to identify up to 530 genes associated with therapy response, providing physicians with necessary insights to determine appropriate treatment for their patients.
"At Quest Diagnostics, we strive to provide comprehensive cancer services that empower providers to work with patients to make optimal care decisions," said Asia Chang, Vice President and General Manager, Oncology at Quest Diagnostics. "We know that positive outcomes in oncology start with excellent diagnostics, but they don't stop there. We're looking forward to providing oncologists at AON and other organizations a single-source ordering and results solution via OncoEMR MPI, as well as the world-class expertise they've come to expect from Quest."
Quest's integration of OncoEMR MPI reflects the company's strategy to make testing simpler and smarter, including through the use of specialized IT and EHR technologies. Last summer, the company began to offer its Haystack MRD test through the Epic Aura platform and now provides a range of specialized tests, from prenatal screening to Alzheimer's disease, through the platform.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
About Flatiron Health
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US, UK, Germany, and Japan, our real-world evidence informs the research, regulatory, commercial, and treatment decisions shaping oncology today. In the US, our point-of-care technology empowers clinicians to deliver smarter, more connected care while generating deeper insights that help advance cancer research. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON's rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com more information, or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.
Quest Diagnostics dosáhla nového 52týdenního maxima 216,87 USD a za měsíc vzrostla o 11,5 %. Firma zároveň čtyřikrát po sobě překonala odhady zisku i tržeb.
Have you been paying attention to shares of Quest Diagnostics (DGX - Free Report) ? Shares have been on the move with the stock up 11.5% over the past month. The stock hit a new 52-week high of $216.87 in the previous session. Quest Diagnostics has gained 24.5% since the start of the year compared to the 1.1% move for the Zacks Medical sector and the 17.8% return for the Zacks Medical - Outpatient and Home Healthcare industry.
What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on April 21, 2026, Quest Diagnostics reported EPS of $2.5 versus consensus estimate of $2.37 while it beat the consensus revenue estimate by 3.14%.
For the current fiscal year, Quest Diagnostics is expected to post earnings of $10.72 per share on $11.84 in revenues. This represents a 8.83% change in EPS on a 7.29% change in revenues. For the next fiscal year, the company is expected to earn $11.56 per share on $12.39 in revenues. This represents a year-over-year change of 7.84% and 4.64%, respectively.
Valuation MetricsWhile Quest Diagnostics has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style.
Quest Diagnostics has a Value Score of B. The stock's Growth and Momentum Scores are C and C, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 20.2X current fiscal year EPS estimates, which is a premium to the peer industry average of 20.1X. On a trailing cash flow basis, the stock currently trades at 14.2X versus its peer group's average of 15X. Additionally, the stock has a PEG ratio of 2.57. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Quest Diagnostics currently has a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Quest Diagnostics meets the list of requirements. Thus, it seems as though Quest Diagnostics shares could have potential in the weeks and months to come.
How Does DGX Stack Up to the Competition?Shares of DGX have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Aveanna Healthcare Holdings Inc. (AVAH - Free Report) . AVAH has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of A, and a Momentum Score of A.
Earnings were strong last quarter. Aveanna Healthcare Holdings Inc. beat our consensus estimate by 38.46%, and for the current fiscal year, AVAH is expected to post earnings of $0.70 per share on revenue of $2.65 billion.
Shares of Aveanna Healthcare Holdings Inc. have gained 30.7% over the past month, and currently trade at a forward P/E of 12.6X and a P/CF of 12.85X.
The Medical - Outpatient and Home Healthcare industry is in the top 18% of all the industries we have in our universe, so it looks like there are some nice tailwinds for DGX and AVAH, even beyond their own solid fundamental situation.
Quest Diagnostics vykázala v prvním čtvrtletí silný růst tržeb z lékařského kanálu a dvouciferný růst tržeb testu AD-Detect na Alzheimerovu chorobu. Zároveň ale zůstává problémem vysoké zadlužení.
Key Takeaways DGX posted strong physician channel growth and expanded hospital and consumer testing initiatives.DGX saw double-digit AD-Detect blood test revenue growth and expanded oncology MRD offerings.DGX is advancing AI, automation and Project Nova while managing a sizable debt load. Quest Diagnostics (DGX - Free Report) is well-poised for growth in the coming quarters, supported by its continued focus on meeting the evolving needs of its core customers — physicians, hospitals and consumers. The company is seeing continued momentum in Advanced Diagnostics, including the strong uptake of the AD-Detect blood test. Efforts to drive operational improvements through the adoption of AI, automation and other technologies also sound very encouraging. Yet, Quest Diagnostics’ solvency level remains a concern. Macroeconomic pressures can weigh on its operations, too.
Over the past year, this Zacks Rank #3 (Hold) stock has rallied 7.7% compared with the industry’s 8.2% growth and the S&P 500 composite’s 23.2% rise.
The renowned provider of diagnostic information services has a market capitalization of $21.59 billion. Quest Diagnostics has an earnings yield of 5.50%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.50%.
Tailwinds Supporting DGXGrowth Momentum in Base Business: Quest Diagnostics delivered high single-digit growth in physician channel revenues in first-quarter 2026, driven by strong demand for innovative testing solutions, expanded health plan access and enterprise account growth. The company also recorded growth in end-stage renal disease, a newer clinical area focused on lab testing for dialysis patients. Volume growth was driven by Fresenius Medical Care’s dialysis network and contributions from newly added independent dialysis clinics and other providers.
In the hospital channel, the company’s flexible solutions allow customers to free up capital while accessing diagnostic innovation and expertise. In early 2026, Quest Diagnostics began scaling its Co-Lab Solutions, including reference laboratory testing, professional laboratory management services, laboratory workforce and supply-chain management, and analytics across all 21 hospitals of Corewell Health.
Image Source: Zacks Investment Research
The consumer-testing platform, QuestHealth.com, continues to gain strong momentum. Quest Diagnostics is deepening partnerships with leading consumer health and wellness brands like WHOOP and OURA Health, integrating its extensive laboratory testing and technology directly into their mobile platforms.
Strong Potential of Advanced Diagnostics: Quest Diagnostics drives growth across its customer channels through fast-growing, advanced diagnostics spanning five clinical areas — advanced cardiometabolic, autoimmune, brain health, oncology, and women's and reproductive health. In brain health, revenues from the AD-Detect blood test for Alzheimer's disease continued to grow at a double-digit rate in the first quarter of 2026.
The cardiometabolic and endocrine portfolio growth was driven by robust demand for tests of Lp(a) and ApoB, as well as for kidney, liver and reproductive hormones.
In oncology, the company continues to build its presence in blood-based minimal residual disease (MRD) testing. In January 2026, new research presented at the ASCO Gastrointestinal Cancers Symposium highlighted the strong clinical value of Quest Haystack MRD in monitoring colorectal cancer. The company also launched the Flow Cytometry MRD blood test for myeloma.
Operational Excellence, a Strategic Priority: Quest Diagnostics’ Invigorate program consistently targets 2% annual savings through structured plans to drive savings and improve productivity across the value chain. The company is deploying automation and AI technologies to improve quality, service, efficiency and the workforce experience. The new Quest AI Companion tool transforms complex biomarker data and reference ranges on test reports into clear, plain language. Quest Diagnostics is scaling the planning and design work for Project Nova, a multi-year initiative to transform its order-to-cash processes and systems and is on track to implement the first wave of solutions in the fall of 2027.
What Ails DGX?Escalating Debt Level: At the end of the first quarter of 2026, long-term debt totaled $5.16 billion, while the cash and cash equivalent balance was only $393 million. The current portion of the debt was $503 million. Debt-to-capital ratio was 42.5%, down sequentially 1.6%. A higher debt level induces higher interest payments, which come along with the risk of failure to pay the same. The times interest ratio, which indicates the company’s capacity to pay interest, was 6.3% in the quarter.
Unstable Macroeconomic Backdrop: As the U.S. healthcare system continues to evolve, Quest Diagnostics faces several inherent risks. Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services. The industry-wide trend of consolidation has resulted in larger insurance plans with significant bargaining power, making it difficult for Quest Diagnostics to negotiate fee arrangements and possibly limiting access to its newer innovative solutions. With the new U.S. administration in place, any changes in U.S. healthcare regulation could have a material adverse effect on the company’s business.
DGX Stock Estimate TrendThe Zacks Consensus Estimate for Quest Diagnostics’ 2026 earnings per share (EPS) has remained constant at $10.72 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $11.83 billion. This suggests 7.2% growth from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 35% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dropped 6.8% against the industry’s 7.8% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy), has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 48.3% against the industry’s 6.4% decline over the past year.
Quest Diagnostics získala v New Yorku schválení pro test Haystack MRD na ctDNA, který pomáhá odhalit zbytkové nebo vracející se onemocnění u solidních nádorů. Test je nyní povolen pro pacienty ve všech 50 státech USA.
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers
, /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
New York maintains a highly rigorous clinical laboratory oversight program, requiring formal technical review and approval of laboratory developed tests before they may be offered to patients in the state. With this approval, Haystack MRD is now authorized for patient testing in all 50 U.S. states. The test was developed under CLIA regulations and has been available for clinician ordering since late 2024 in 49 states and the District of Columbia.
"This approval represents the culmination of our many years of hard work and commitment to delivering a highly accurate test that can meaningfully improve patient care," said Dan Edelstein, Vice President and General Manager for Haystack Oncology, a Quest Diagnostics company. "Haystack MRD was designed to give oncologists the confidence to detect residual disease earlier, catch recurrence before it becomes clinically apparent, and help identify response to treatment. New York's approval is another proof point for Haystack MRD's quality and technical sophistication, and we look forward to extending access to this important innovation for clinicians and patients in the state."
In addition, Haystack MRD's clinical utility has been demonstrated in rigorous investigational settings, including the landmark study of non-operative management of patients with locally advanced mismatch repair–deficient (dMMR) solid tumors, which was led by Dr. Andrea Cercek and colleagues at Memorial Sloan Kettering Cancer Center and published in The New England Journal of Medicine in May 2025. In that study, ctDNA testing, using Haystack MRD, was found to be a "reliable liquid biopsy surrogate" that identified clinical complete response at a median of 1.4 months, compared to more than 6 months using imaging methods.
"In our study of non-operative management for dMMR solid tumors, the use of MRD testing provided additional molecular information that complemented traditional assessments such as imaging and endoscopy," said Dr. Cercek, Medical Oncologist, Memorial Sloan Kettering Cancer Center. "For patients who may avoid surgery, having multiple tools to evaluate treatment response and monitor for recurrence is important. These findings highlight the crucial role of MRD testing in informing patient management and underscore the need for continued study as these approaches are integrated into clinical practice."
About Haystack Oncology
Haystack Oncology represents the culmination of over 20 years of collaboration to advance technical and clinical development in liquid biopsy technologies by cancer genomics pioneers at Johns Hopkins School of Medicine. The company, a wholly owned subsidiary of Quest Diagnostics, developed Haystack MRD, a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual or recurrent disease with exceptional sensitivity and specificity. Haystack Oncology works with biopharmaceutical companies to accelerate and inform clinical development programs and advance important therapeutics to global markets, from early phase clinical development to companion diagnostics. Haystack MRD was developed and validated in a CLIA-certified laboratory and is available for commercial use as a lab-developed test (LDT) by Quest Diagnostics. The FDA granted Haystack MRD Breakthrough Device Designation in 2025 for use in Stage II colorectal cancer. Haystack MRD is also available for clinical trials as an investigational device by Haystack Oncology in laboratories located in Baltimore, Maryland; Hamburg, Germany; and Helsinki, Finland. www.haystackmrd.com
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
